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ABSTRACT 
 
 
Marihuana continues to be a controversial topic in today’s society.   The plant 
material is used recreationally as a stupefacient and has a purported medicinal use.  In 
fact, anecdotal information about its medicinal properties has been such that Health 
Canada has recently started an initiative to provide a well characterized supply of plant 
tissue to researchers interested in examining its potential medicinal properties.  
Simultaneously this same material is being provided for those subjects who are licensed 
to use marihuana as a medicine.   
In order to further study marihuana and its component cannabinoids it is essential 
to be able to discern both the cannabinoid content in the product being supplied and 
more importantly the cannabinoid profile in the delivery system.  At present the most 
common route of administration is via inhalation of the combusted plant material.  
Consequently methods capable of measuring the cannabinoid content in combusted plant 
material would be very useful in order to make meaningful study of the 
pharmacokinetics of the cannabinoids delivered by this route.   
Investigations were carried out to develop a method and study the volatile 
constituents of combusted marihuana plant material in a semi-enclosed environment.  
Thus the hypothesis of this research is that qualitative and quantitative information can 
be obtained from the combustion products of cannabis plant tissue.  The method relies 
upon the solid phase extraction of smoke arising from the combustion of plant material 
in a variety of combustion chambers.  The combustion chambers were designed to 
reflect the current marihuana “paraphernalia” in use as well as a high efficiency in vitro 
system.  Both the qualitative and quantitative levels of a limited number of cannabinoids 
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were evaluated before and after combustion.  A quantitative Liquid Chromatography 
Ultra Violet (LC-UV) detector method was validated for the analysis of a selected group 
of cannabinoids ( Δ9-tetrahydrocannabinol (THC), cannabinol (CBN), cannabidiol 
(CBD) and tetrahydrocannabinolic acid (THCA) .  When this method was applied to 
plant material available through the medical marijuana initiative the following 
observations were made on the combustion products:   
MATERIAL 
ANALYZED 
CBD μg/mL CBN (μg/mL) THC (μg/mL) THCA (μg/mL)
PLANT BLQ BLQ BLQ 890 
COMBUSTED 20 14 420 28 
• 5 mg plant tissue extracted using a validated HPLC-UV method 
• 5 mg plant tissue combusted in  a closed combustion chamber. 
• BLQ: below level of quantification (<12.5 μg/mL) 
 
These results sparked further research into the quantitative transformation of 
cannabinoids during the combustion process.  In this regard, it was shown that THC, 
CBD and CBN all could be recovered at approximately a 90% ratio upon combustion  
However, THCA was thermally converted such that very little remains after combustion 
and furthermore, its degradation product, THC can only account for 50% of the THCA.  
The latter observation is important since there has been a prevailing thought that THCA 
is quantitatively transformed during combustion to THC while in fact this transformation 
is approximately 50%.  This finding must be considered when pharmacokinetic studies 
are carried out using inhalation of combusted plant material as the delivery system. 
 A further finding of this research is that not all popular combustion devices yield 
identical quantitative cannabinoid profiles.  In this regard, the simpler “pipe” systems 
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result in the highest yields of heat transformed cannabinoids while the vaporizer systems 
have the lowest cannabinoid yields.   
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1 INTRODUCTION 
 
1.1 Background 
The subject of marihuana is a controversial topic in today’s society.  It is 
legalized in some parts of the world and illegal in others.  Research on marihuana 
reached its peak during the 1970’s and 1980’s but then it was largely abandoned for a 
number of years.  However, the plant from which marihuana originates, cannabis sativa, 
has been having a rebirth in popularity in Canadian society.  There are a growing 
number of people who believe marihuana should be decriminalized much the same way 
alcohol was so many years ago.  The reason people want to decriminalize it is for its 
possible therapeutic benefits that are just now starting to be explored and examined 
through science and research.  As a result of this, it is now possible via special 
permission from the government, to obtain a certificate allowing an individual to legally 
possess marihuana for its use as a potential therapeutic agent:  
On July 30, 2001, the Narcotic Control Regulations was amended and the Marihuana Medical Access 
Regulations came into force. These regulations established a compassionate framework to allow the 
use of marihuana by people who are suffering from serious illnesses and where the use of marihuana is 
expected to have some medical benefit that outweighs the risk of its use.  
Under the new regulations, those who fall into one of two categories can apply for an Authorization to 
Possess marihuana for medical purposes. Holders of this authorization may possess a maximum 30-
day treatment supply of marihuana at any given time. 
Category 1: This category is comprised of any symptoms treated within the context of providing 
compassionate end-of-life care; or the symptoms associated with the specified medical conditions 
listed in the schedule to the Regulations, namely: 
• Multiple Sclerosis: severe pain and/or persistent muscle spasms  
• Spinal Cord Injury: severe pain and/or persistent muscle spasms  
• Spinal Cord Disease: severe pain and/or persistent muscle spasms  
• Cancer: severe pain, cachexia, anorexia, weight loss, and/or severe nausea  
• AIDS/HIV infection: severe pain, cachexia, anorexia, weight loss, and/or severe nausea  
• Severe forms of Arthritis: severe pain  
• Epilepsy: seizures  
Category 2: This category is for applicants who have debilitating symptom (s) of medical condition 
(s), other than those described in Category 1. Under Category 2, persons with debilitating symptoms 
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can apply to obtain an Authorization to Possess dried marihuana for medical purposes, if a specialist 
confirms the diagnosis and that conventional treatments have failed or judged inappropriate to relieve 
symptoms of the medical condition. While an assessment of the applicant's case by a specialist is 
required, the treating physician, whether or not a specialist, can sign the medical declaration. 
 (Health Canada, Office of Cannabis Medical Access, 28/02/06) 
As one can see, this type of regulation clearly has put marihuana back on the research 
hot list indicating that appropriate therapeutic protocols need to be established and 
determined.  The exact mechanisms or mode of action of marihuana in treating or 
alleviating symptoms from any of the above conditions are not clearly understood but 
may relate to the endogenous cannabinoid receptors which have been recently identified 
and studied. 
 In order to obtain marihuana legally for medical use, an individual must apply 
for a permit.  Health Canada requires some or all of the following forms to be 
completed: 
 
Form A: Application for the Authorization to Possess Marihuana 
Form B: (B1,B2,B3) These are the medical support forms that are filled out by the 
patient’s physician(s), doctor(s) and/or specialist(s). 
Form C: Application for Licence to Produce Marihuana by Applicant (for growing ones 
self) 
Form D: Application for Licence to Produce Marihuana by Designated Person (to be 
completed by the person growing marihuana) 
Form E: Consent of Property Owner to grow marihuana (for renters) 
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 If the individual only wishes to possess marihuana for medical purposes, form A and B 
must be completed.  If the individual is applying to both possess and grow his/her own 
marihuana for medical purposes, forms A, B, C, (and E, if applicable) must be 
completed. 
If the individual is applying to possess dried marihuana for medical purposes and would 
like another person to grow the marihuana for him/her, forms A, B, D (and E if 
applicable) must be completed.  The forms are available from Health Canada at:  
http://www.hc-sc.gc.ca/dhp-mps/marihuana/index_e.htmL 
 
1.2 Cannabinoid Pharmacology 
In human’s, two cannabinoid receptors have been identified, CB1 and CB2 
receptors.  CB1 receptors are found mainly on neurons in the brain, spinal cord and 
peripheral nervous system, but are also present in certain peripheral organs and tissues, 
among them endocrine glands, leucocytes, spleen, heart and parts of the reproductive, 
urinary and gastrointestinal tracts (Pertwee, 1997).  CB2 receptors are found mostly in 
areas related to the immune system, in particular, leucocytes, spleen and tonsils 
(Pertwee, 2002)  (Gallieque, 1995).  Activation of the CB1 receptor produces the 
psychotropic effects that are normally attributable to the “high” feeling often associated 
with the recreational use of marihuana in human.  The major cannabinoid that binds to 
the CB1 and CB2 receptors is Δ9-tetrahydrocannabinol (THC).  Beyond the CNS effects 
of THC it can also induce tachycardia, increase cardiac output and can produce 
peripheral vasodilation (Perez, 1999).   It is unclear the exact role the CB2 receptor 
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subtype plays although it may play a role in analgesia, anti-inflammatory and 
antineoplastic actions (Sanchez, 2001).   
More recently, there is evidence suggesting that cannabinoids can modulate 
synaptic transmission, the cardiovascular system, and the immune system through 
receptors distinct from CB1 and CB2.  There may be an additional "independent" 
endocannabinoid signaling system that involves other “independent” endocannabinoids 
distinct from anandamide and 2-arachidonoyl-glycerol (Mackie, 2006). 
 
1.3 Endocannabinoids 
After identification of the CB1 and CB2 receptors, endogenous ligands were also 
discovered for these receptors (Devane, 1992, Sugiura, 1995).  The most important 
ligand discovered was anandamide.   Anandamide has moderate affinity for the CB1 
receptor and is rapidly metabolized.  It shares most of the pharmacological effects of 
THC (Devane, 1992).   Anandamide can be inactivated in the brain via two pathways.  It 
can be either enzymatically cleaved to arachidonic acid and ethanolamine or it can be 
inactivated via neuronal uptake (Marihuana and Medicine, 2000).  In general, the 
affinity of anandamide for cannabinoid receptors is only ¼ to ½ that of THC (Pertwee, 
1997).  Interestingly, the structure of anandamide (see figure 1.1) is not very similar to 
THC.  This observation is similar to the relationship noted for opiod compounds and the 
corresponding endogenous ligand known as endorphins.  Other endocannabinoids have 
also been discovered:  2-arachidonyl-glycerol (2-AG), homo-γ-linolenylethanolamide 
and 7,10,13,16-docusatetranylethanolamide (Hanus, 1993, Mechoulam, 1995).   
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Figure 1.1 chemical structure of Anandamide 
 
 
 
1.4 Therapeutic Benefits of THC 
Marihuana has been recognized as a potential therapeutic agent in a number of 
disorders.  Very few well controlled studies have been conducted regarding its 
therapeutic benefits.  The reason for this is because it is difficult to study marihuana 
without having to deal with the legal ramifications due to its status as being an illicit 
drug.  The inherent difficulty in carrying out well controlled studies with a natural 
product also impedes advancements in the therapeutic use and study in humans.   
Marihuana plant contains many different chemical entities in varying concentrations.  To 
complicate matters, the concentration of each chemical entity varies between different 
plant samples.  
One of the major effects of THC is analgesia.  Therefore, it has been indicated for 
use in chronic pain type disorders.  Clinical studies should be directed at pain patients 
for whom there is a demonstrated need for improved management and where the 
particular side effect profile of cannabinoids promises a clear benefit over current 
approaches. The following patient groups have been identified as potential target groups 
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for further clinical studies of cannabinoids in the treatment of pain (Marihuana and 
Medicine, 2000):  
• Chemotherapy patients, especially those being treated for the mucositis, nausea, 
and anorexia.  
• Postoperative pain patients (using cannabinoids as an opiod adjunct to determine 
whether nausea and vomiting from opiods is reduced).  
• Patients with spinal cord injury, peripheral neuropathic pain, or central post 
stroke pain.  
• Patients with chronic pain and insomnia.  
• AIDS patients with cachexia, AIDS neuropathy, or any significant pain problem.  
 
1.5 Evaluation of the Potential Therapeutic Use of Cannabinoids 
 
Pain can be treated via a number of different approaches.  The classic opiod 
painkillers such as morphine, fentanyl, codeine and oxycodone can have limited success 
in patients due to unwanted side effects such as nausea, constipation, potential addiction 
and tolerance.  It is for this reason that cannabinoids could be very successful candidates 
as adjuncts to opiods in the treatment of pain.  There have been no well designed studies 
on the use of cannabinoids in post operative pain so it is uncertain as to their value in 
treating this condition.  There have been a number of studies undertaken for cannabinoid 
use in chronic pain.  Unfortunately, all of the studies are small and poorly constructed in 
general.  In a study by Campbell a group of 10 cancer patients with chronic pain 
received a placebo, 5, 10, 15 and 20 mg of THC.  Each subject had no idea which dose 
they were given in each successive trial.  The 15 and 20 mg doses produced significant 
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analgesia with no cases of nausea or vomiting commonly encountered when opiods are 
used to treat chronic pain (Campbell, 2001).  In April 2005, Health Canada approved 
cannabis medicinal extract (CME) with the indication of adjunctive treatment for 
symptomatic relief of neuropathic pain in adults with multiple sclerosis.  It is a 
sublingually dosed whole-plant extract that contains a 1:1 ratio of THC and CBD.  
Notcutt et al designed a double blind placebo controlled crossover study of 34 patients 
with chronic stable pain who were poorly responsive to other treatments.  Patients 
selected their 2 worst symptoms on which to record daily pain ratings.  Patients also 
titrated their CME dose from 1 to 8 sprays per dose.  There were significant 
improvements in the ratings of the two self selected symptoms with CME (Notcutt, 
2004).  Unfortunately, interpretation of these results is somewhat complicated as there 
was no standard dose.  However, an inference can be made that the CME helped with 
the 2 patient self selected pain symptoms compared to placebo.   
There is a growing body of evidence that cannabinoids may actually play a role 
as anticancer agent(s).  In vitro and in vivo studies have found that naturally occurring 
and synthetic cannabinoids have antineoplastic effects in mice given xenografts of lung 
carcinomas, gliomas, thyroid epitheliomas, lymphomas and skin carcinomas (Guzman, 
2003).  The exact mechanism of these anti-neoplastic effects is unknown. 
 Nausea and vomiting can be caused by a wide variety of conditions, such as 
viral illness, cancer, radiation exposure, medications, motion sickness and poisoning.   
The anti-emetic effect of THC can be considered weak.  In one study, prochlorperazine 
and THC were used to treat chemotherapy induced emesis.  The results were quite poor 
as both agents failed to stop vomiting in two thirds of patients (Frytek, 1979).  In another 
study comparing THC to metoclopramide (a well known anti-emetic agent), complete 
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control of emesis occurred in 47% of those treated with metoclopramide and 13% in 
those treated with THC (Grala, 1984).   After this study, the FDA approved the use of 
THC in an oral dosage form known as dronabinol as an agent suitable for chemotherapy 
induced emesis.   New classes of anti-emetics (in particular the serotonin receptor 
antagonists) have become the gold standard for chemotherapy induced emesis.  As a 
result, THC should be considered to have weak anti-emetic properties and its use is best 
reserved for adjunct therapy when other methods have been tried unsuccessfully. 
 Wasting syndrome in acquired immune deficiency syndrome (AIDS) patients is 
defined by the Center for Disease Control and Prevention as the involuntary loss of more 
than 10% of baseline average body weight in the presence of diarrhea or fever of more 
than 30 days that is not attributable to other disease processes (CDC, 1993).  In two 
studies by Beal et al, it was demonstrated that dronabinol clearly helps to battle AIDS 
induced anorexia and this effect has now been approved by the FDA (Beal, 1995, 1997). 
Other therapeutic benefits that are currently being explored are the ability of 
marihuana to help spasticity due to spinal cord injury and multiple sclerosis (Killestein, 
2002).  Much of the evidence stating that marihuana may be beneficial for treatment of 
multiple sclerosis is largely subjective involving small groups.  Currently, a number of 
large-scale phase III clinical trials are under way to further elucidate the use of 
cannabinoids in the symptomatic treatment of multiple sclerosis.  
It is also known that THC has a favourable effect on intraocular pressure 
(Crawford, 1979) which plays an important role in glaucoma treatment.  Unfortunately, 
the more mainstream agents (timolol, latanoprost, brimonidine) used in treating 
glaucoma have greater efficacy since marihuana may leave the patient with the 
undesirable psychotropic effects of marihuana. 
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There has also been some evidence that marihuana may play a role in helping to 
alleviate seizures in epilepsy patients. (Gordon, 2001).   This aspect of the drug is 
largely unstudied and more clinical trials would need to be carried out before any 
conclusions could be determined. 
 
1.6 Cannabinoids Of Interest 
A total of 66 phytocannabinoids have been identified.  Most of the 66 identified 
fall into a number of subclasses or types:  the canabigerol (CBG), cannabichromene 
(CBC), cannabidiol (CBD), ∆9 – tetrahydrocannabinol (THC), cannabinol (CBN), ∆8 – 
tetrahydrocannabinol, cannabicyclol, cannabielsoin, , cannabinodiol and cannabitriol 
types.  (A total of nine cannabinoids belong to the ∆9 – tetrahydrocannabinol group, with 
side chains of one, three, four and five carbons (Grotenherman, 2003).  There are two 
numbering systems commonly used when it comes to numbering the carbon atoms in 
cannabinoid compounds.  The first system is the monoterpene system (Figure 1.2) which 
was used and created as a consequence of the biosynthetic pathway in plants for the 
synthesis of cannabinoids. 
  
Figure 1.2 Monoterpenoid chemical numbering system 
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The second system is the dibenzopyran system based on IUPAC nomenclature and 
numbers the carbons in the following fashion (Figure 1.3): 
 
Figure 1.3 Dibenzopyran chemical numbering system 
 
 
Throughout this paper, all structures will be referenced using the dibenzopyran system.  
As a result of the two numbering systems, it is important to realize that ∆9 THC and ∆1 
THC are the same molecule that have been numbered using either numbering system.  
The majority of the literature uses the ∆9 THC dibenzopyran nomenclature. 
The cannabinoids found in greatest abundance in a typical marihuana plant 
sample are ∆9 – tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) 
(Figure 1.4).  As well, there are often small amounts of cannabichromene (CBC) and 
canabigerol (CBG) (Figure 1.5).  The major most acidic cannabinoid found is ∆9 -
tetrahydrocannabinolic acid (THCA-A) (Figure 1.6).  
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Acidic cannabinoids are the major constituents in cannabis sativa plant with high 
concentrations found in the leaves and buds; however they readily undergo 
decarboxylation to their respective neutral cannabinoids upon mild to extreme heating.  
THCA is pharmacologically inactive; however after it is decarboxylated it forms the 
pharmacologically active THC (Nova Institute: THC-Limits for food part 2, 2002) 
(Figure 1.7).  THCA exists as two geometric isomers THCA-A and THCA-B differing 
only in the location of the carboxylic acid group in either the 2(THC-A) or 4(THCA-B) 
positions. 
Cannabidiol (CBD) is a nonpsychotropic cannabinoid, for which sedating, 
antiepileptic, antidystonic, antiemetic and anti-inflammatory effects have been observed. 
It reduces intraocular pressure, is neuroprotective and antagonizes the psychotropic and 
several other effects of THC. Anxiolytic and antipsychotic properties might prove useful 
in psychiatry (Grotenhermen, 2003). 
The nonpsychotropic cannabinoids CBG and CBC show sedative effects. CBG 
has been observed to decrease intraocular pressure, show antitumour activity against 
human cancer cells and has antibiotic properties (Grotenhermen, 2003). 
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Figure 1.7 Decarboxylation of THCA to THC 
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THC is considered to be the source of the main pharmacological effects observed 
after the consumption of cannabis.  This includes the marihuana-like “high” action and 
at least part of the medicinal properties of the plant.  Cannabinoids exert many effects 
through the activation of G protein coupled cannabinoid receptors in the brain and 
peripheral tissues (Figure 1.8). 
 
 
 
Figure 1.8 Cannabinoid agonists trigger a series of reactions within cells. Cannabinoid receptors are 
embedded in the cell membrane, where they are coupled to G proteins (G) and the enzyme adenylyl 
cyclase (AC). Receptors are activated when they bind to ligands, such as anandamide or THC in this 
case. This triggers a variety of reactions, including inhibition (—) of AC, which decreases the 
production of cAMP and cellular activities dependent on cAMP; opening of potassium (K+) 
channels, which decreases cell firing; and closing of calcium (Ca2+) channels, which decreases the 
release of neurotransmitters. Each of those changes can influence cellular communication.  (copied 
with permission from Marihuana and Medicine: Asessing the Science Base, 1999, Institute of 
Medicine (IOM), USA) 
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  Additionally, there is evidence of non-receptor dependent mechanisms.  For example, 
neuroprotective effects in ischemia and hypoxia (Hampson, 2002), effects on the 
immune system, and some effects on circulation (Ralevic, 2002).    
 
1.7 Pharmacokinetics of THC 
Cannabis plant is usually administered via inhalation or taken orally.  It is 
inhaled by smoking a marihuana cigarette or taken orally as capsules or in baked foods 
or liquids.  THC is detectable in plasma almost immediately after smoking due to the 
fast permeability across the lung mucosa (Huestis, 1992).  Peak plasma concentrations 
occur 3-10 minutes after onset of smoking.  Psychotropic effects begin immediately, 
reach a maximum after 15-30 minutes and taper off within 2-3 hours (Grotenherman, 
2003).  Systemic bioavailability generally ranges between 10-35% (Lindgren, 1981).    
 Oral administration results in slow and erratic absorption with maximal plasma 
concentrations usually seen after 1-2 hours (Sporkert, 2001).   Extensive first pass 
metabolism results in low bioavailability compared to the initial dose.  Psychotropic 
effects set in with a delay of 30-90 minutes and reach their maximum after 2-3 hours and 
last for about 4-12 hours depending on dose (Grotenherman, 2003).     
 
1.8 Metabolites  
THC is metabolized in the liver by microsomal hydroxylation and oxidation via 
the CYP450 system.  A member of the CYP2C subfamily of isoenzymes plays the major 
role for its metabolism in humans (Watanabe, 1995).   The 11th carbon on the THC 
molecule is the major site of metabolic attack.  The two major metabolites of THC are 
11-hydroxy-delta-9-THC and 11-nor-9-carboxy-delta-9-THC (Niveau, 2002) (see Figure 
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1.9).  Hydroxylation of the 11th carbon followed by oxidation to the acid moiety allows 
for glucuronidation to occur.  THC is excreted within days and weeks, mainly as acid 
metabolites.  Approximately one third of THC metabolites are excreted in the urine and 
about 65-80% is eliminated in the feces.  Less than 5% of an oral dose of THC is not 
metabolized and is eliminated in the feces (Wall, 1983). 
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Figure 1.9 Metabolism of THC in the liver and lungs 
 
 
1.9 Mainstream Smoke 
A common method of taking or using marihuana is by the inhalation route.  Very 
little research has been carried out on determining cannabinoid profiles or relative 
concentration of cannabinoids in the smoke resultant from the combustion of plant 
material.  In this regard, a key question relates to whether there is a difference in the 
Δ9-THC 11-hydroxy-Δ9-THC 
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cannabinoid profile of cannabis sativa plant before and after combustion.  In fact, 
throughout the literature, it is assumed that the total of the THC and its corresponding 
acids is almost always considered in potency content.  However, very few reports 
acknowledge that the conversion of THCA to THC is not a 100% quantitative.   
Therefore, throughout the literature it has been assumed that however much THCA and 
THC is in the plant is the total amount that is delivered in the smoke.  This is likely an 
oversimplification.   Recently a study by Dussy et al showed that maximal conversion in 
a optimized analytical equipment setup yields about 70% conversion from THCA to 
THC.  Furthermore, in the simulation of the actual smoking process, only about 30% of 
the spiked THCA substance could be recovered as THC (Dussy, 2004). 
 
1.10 Sidestream Smoke 
Interest in sidestream smoke or passive inhalation of combusted plant material 
primarily arises as a consequence of litigation.  The argument that the cannabinoids 
found in an individual’s urine arose due to the person’s presence in an area where 
marihuana was being smoked was typified by the 1998 winter Olympics incident.  In 
1998, there was a Canadian athlete in the Winter Olympic Games who was stripped of 
his medal for testing positive for THC.  It was argued that the individual never in fact 
smoked any marihuana but had been exposed to it via sidestream smoke.  In the end, the 
person was allowed to keep the medal as the sidestream smoke argument held up.  
However, with that being said in one study, 5 drug free volunteers were passively 
exposed to the sidestream smoke of 4 and 16 marihuana cigarettes containing 2.8% THC 
for one hour each day for six consecutive days.   The room size in which they were 
exposed to the cannabis smoke had dimensions of 2.1m x 2.5m x 2.4m which is a 
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volume of roughly 12,225 liters.  The study showed that significant amounts of THC 
were absorbed by all subjects exposed to the 16 cigarette setup.  At the 4 cigarette setup, 
the subjects tested positive only infrequently or were negative.  Furthermore, in the 16 
cigarette setup, the subjects complained that the smoke in the room was so thick that it 
would be impossible to not knowingly be inhaling the smoke when surrounded by such a 
thick cloud (Cone et al, 1986).   This study was repeated two more times with nearly 
identical results (Cone et al, 1987).  Therefore this would suggest that although 
sidestream smoke can produce measurable levels of cannabinoid in vivo the 
individual(s) would consciously know they were in a room with cannabis smoke.  
Furthermore, conducting oral fluid testing for presence of THC in passive versus active 
subjects clearly shows a direct relationship between oral fluid concentrations and urine 
analysis in an active smoker versus a passive smoker (Niedbala, 2005). 
 
1.11 Methods Used in the Chemical Analysis of Cannabis 
 
In the past, the vast majority of cannabinoid analytical studies have been carried 
out using gas chromatography (GC) as the primary means to separate the cannabinoid 
compounds.  This method relies upon the volatility of the various cannabinoids and 
readily converts the non-volatile carboxylic acids to their respective volatile 
counterparts.  However, it is also important to realize that cannabinoids are very heat 
labile compounds, in particular the acid entities.  As a result, it is extremely difficult to 
get a true measurement of the cannabinoids in a plant sample without thermally 
decomposing  apriori or derivatizing the sample so as to protect the thermally labile 
acids.   This is more readily accepted if you are working with one compound; however, 
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derivatizing a plant sample that contains numerous cannabinoid compounds makes 
derivatization a poor choice because you do not know what exactly is being derivatized 
or whether the derivitization is quantitative.  There are some 421 identified compounds 
in cannabis, 66 of which are cannabinoids (Turner, 1982).  Unfortunately, the research 
community continues to use GC as a means to qualitatively and quantitatively 
characterize cannabinoids.  The primary reason for this is because derivatizing using GC 
has been carried out so frequently that it is an accepted method.   
A method by LeBelle and Savard named “Gas Chromatographic Determination 
of Tetrahydrocannabinol in Cannabis” is one example of many of the flaws mentioned 
above.   This method uses GC-FID as a means to quantify the THC content in cannabis 
plant material.  The first problem is it is assumed that THCA is found in small quantities 
in cannabis when in fact it is usually in the largest abundance of all cannabinoids.  The 
second problem is there is no mention of any derivitization which means the 
cannabinoids are being injected onto a 200°C column with a temperature program up to 
290°C in 8 minutes.   This will most certainly lead to thermal destruction of the 
cannabinoids.  Third, the way in which the standards of THCA and THC are used in 
order to calculate the percent conversion of THCA to THC is severely flawed.  The way 
the percent conversion is calculated is by injecting a known amount of THC on the 
column and then a known amount of THCA on the column and then taking the ratio of 
peak areas.  It is stated that the conversion should be 90% or greater for THCA to THC 
but the larger problem here is no account is made for the thermal destruction of both 
compounds to unknown quantities.  Thermal destruction in underivatized samples is a 
very big problem and this method of GC quantification and analysis is essentially 
useless with cannabinoid compounds without derivatization.  In a recent study by Dussy 
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et al, they determined that maximal conversion from THCA to THC inside a GC system 
to be approximately 67% at an injector temperature of 220 °C with the remainder of the 
products being lost to thermal destruction and the creation of polymeric material (Dussy, 
2004).  It has not been until more recently that people are starting to use HPLC as a 
means to separate and quantify the cannabinoids. 
 
1.12 High Performance Liquid Chromatography Instrumentation in Marihuana 
Analysis 
 
High performance liquid chromatography (HPLC) is becoming more commonly 
used for marihuana analysis.  A major advantage of HPLC over gas chromatography in 
cannabinoid analysis is that acidic cannabinoids can be detected which is not the case in 
gas chromatography.  A method developed by Dautbegovic et al in 2002, is presented to 
illustrate HPLC instrumentation.  A solvent pump, an injector, variable-wavelength 
ultraviolet (UV) detector set at 230 nm, a column (4.6 x 150 mm), and data processor 
make up the HPLC instrument used in this particular analysis.  A flow rate is set at 1.5 
mL/min and mobile phase consists of 65 % acetonitrile, 35 % water with 0.03% formic 
acid.   
The mobile phase, column, flow rate and a detector can be varied depending on 
desired specificity and selectivity for the analytes in question.  Therefore, the HPLC 
system may be modified to allow for separation of numerous analytes.   
 
1.13 The Devices Used for Combusting and Inhaling 
The combustion and inhalation of marihuana smoke can be accomplished in a 
number of ways.  The most common practice is to “roll” plant material into a cigarette 
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and smoke it in a manner similar to a tobacco cigarette.  Alternatively, pipes, water 
bongs and vaporizers are also used to combust the marihuana material.  The end result is 
the same in that marihuana is converted from a solid to a gaseous state and the gas is 
inhaled into the lungs by an individual.  Some find water bongs or vaporizers are more 
comfortable as the smoke is less irritating to the mucosa lining the respiratory tract and 
the mouth. 
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2 RATIONALE AND OBJECTIVES OF THE STUDY  
 
This project was undertaken to examine cannabinoid content in combusted plant 
material obtained through the Health Canada medicinal marihuana initiative.  In order to 
carry out this project, it was necessary to develop a reliable combustion method and 
technology to trap and extract cannabinoids from the smoke.   This work is deemed 
essential in order to evaluate the dosing of subjects using cannabis since the most 
common way of ingesting marihuana in people is by smoking.  To the best of our 
knowledge, no work has ever been done on the actual THC content of marihuana smoke.  
It is known that by burning cannabis plant material, much of the THCA found in the 
plant is converted to THC which is the pharmacologically active stupefacient ingredient 
in cannabis whereas the THCA is considered a “pro-drug”.   It is hoped that by 
analyzing the smoke of combusted cannabis plant tissue extract, similar chemobotanical 
profiling data as that currently available for uncombusted plant tissue can be obtained.  
In the plant tissue, there are other compounds in cannabis extract (CBD, CBN, etc) 
which may also be affected by heat.  These compounds could also display important 
pharmacological activity.  It is hoped that if a reliable, reproducible model of 
quantifying the smoke can be established, these results could be correlated with the 
compounds found in the cannabis plant extract and a relationship could be established.  
 Thus it is possible to summarize the research proposal as follows: 
The hypothesis of this research is can qualitative and quantitative changes be analyzed 
and measured from the combustion products of cannabis plant tissue.  More specifically, 
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upon the combustion of marihuana plant tissue is the conversion of THCA to THC 
100% quantitative and furthermore, are there qualitative and or quantitative conversions 
of cannabinoids in the plant after combustion? 
 
Therefore, in summary the major objective required in this project are the following 
• Creation of a method to reliably capture and sample smoke produced from 
burning cannabis plant material.   
• Use both an HPLC-UV and LC-MS-MS method to both qualitatively and 
quantitatively measure the components found in the cannabis smoke.  
• Apply the above methods to a standardized sample of cannabis plant material. 
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3 EXPERIMENTAL 
 
3.1 Chemicals and Reagents 
Table 3.1 lists the various chemicals and reagents used in the work described in 
the thesis.  The name, grade, and source of each chemical and reagent are identified in 
the table.  All chemicals and reagents were used without further purification or 
processing. 
 
Table 3.1 Table of chemicals and reagents used in the thesis 
Name of the 
chemical/reagent 
Grade Source 
Methanol Omnisolve EM Science 
Acetonitrile HPLC EM Science 
Water RO de-ionized Bronstead/Thermodyne Nanopure® water system 
Formic acid 98-100% EM Science 
Nitrogen gas Commercial Praxair, Saskatoon, SK 
 
All EM Science chemicals and reagents were purchased from VWR in Edmonton, 
Alberta. 
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3.2 Instrumentation 
The HPLC instrumentation was composed of a Millipore Waters Model 590 pump, 
Millipore Waters Lambda Max 480 spectrophotometer set at 230 nm, C8 reverse phase 
column (4.6mmX150mm, Zorbax), and Shimadzu SIL-9A autoinjector.  Data 
acquisition and processing were automated through the use of Waters Empower 
chromatography software.  The pump, spectrophotometer, column, and chromatographic 
software were purchased from Waters in Mississauga, Ontario.  The auto-injector was 
purchased from Mandel in Guelph, Ontario. 
Table 3.2 lists the various pieces of instrumentation used in processing and 
handling of the samples described in the thesis.  The names of the instrumentation, the 
source, and addresses of the suppliers are indicated. 
 
Table 3.2 Table of instrumentation used in the processing and handling of the samples 
Name of the Instrument Source Address 
IKA-Vibrax-VXR shaker VWR Edmonton, AB 
Laboratory refrigerator set at 4°C 
with a separate freezer 
compartment 
VWR Edmonton, AB 
15mL disposable borosilicate 
glass culture tubes (size: 16 x 
125mm) 
VWR Edmonton, AB 
Polypropylene stoppers (size: 
16mm) Canadawide Scientific Ottawa, ON 
Eppendorf standard tube, 500 
microcentrifuge tubes natural 
polypropylene (1.5mL) 
VWR Edmonton, AB 
Kimble septa 10” PTFE VWR Edmonton, AB 
Kimble insert vial, clear 
(0.3mL, 8mm) VWR Edmonton, AB 
Chromacol crimp top caps with 
Teflon/rubber septum VWR Edmonton, AB 
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Pasteur Pipet VWR Edmonton, AB 
Eppendorf 2-20uL pipettor using 
Biorad BR-41 pipet tips BioRad Mississauga, ON 
Eppendorf 20-200uL pipettor 
using Biorad BR-41 pipet tips 
 
BioRad Mississauga, ON 
Eppendorf 100-1000uL pipettor 
using Biorad BR-39 pipet tips BioRad Mississauga, ON 
Eppendorf repeater pipet using 
Eppendorf 2.5mL combitips plus VWR Edmonton, AB 
Hamilton gas tight syringes (500 
μL) VWR Edmonton,AB 
Kimble 1.8mL Robo® vial 
amber (12x32 mm) with 
Teflon/rubber septum 
VWR Edmonton,AB 
Kimble 20mL glass scintillation 
vials with Teflon screw caps VWR Edmonton,AB 
Pyrex 2000 mL glass bottle VWR Edmonton,AB 
Kimax-35 1000 mL glass bottle VWR Edmonton,AB 
Kimax 1000mL graduate 
cylinder VWR Edmonton,AB 
Kimax 2000mL graduate 
cylinder VWR Edmonton,AB 
Pyrex 1000mL filter flask VWR Edmonton,AB 
MFS Micro Filter System VWR Edmonton,AB 
PALL Nylaflo® nylon 
membrane filter (0.2μm, 47mm) VWR Edmonton,AB 
Cole Parmer Digi-sense 
thermometer Type K 
Thermocouple 
Cole Parmer Missisauga, ON 
Gas sampling bulb Cole Parmer Missisauga, ON 
Savant 190 Vacuum Pump Savant Missisauga, ON 
3M solid phase extraction 
cartridge size 3mm x 7mL 3M Missisauga,ON 
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Isolute solid phase extraction 
cartridge size 3mm x 7 mL VWR Missisauga,ON 
 
 
3.3 Solutions 
3.3.1 HPLC Mobile Phase Solution 
 
HPLC mobile phase solution consisted of 65 % acetonitrile and 35 % of aqueous 
0.12 % formic acid solution.  The HPLC mobile phase solution was prepared by 
measuring 700 mL deionized reverse osmosis (RO) water in a graduate cylinder, which 
was then transferred into a filter flask and 2.38 mL of formic acid was added to the 
water.  1300 mL of acetonitrile was measured in a graduate cylinder and added to the 
702.38 mL of the above prepared aqueous solution.  The mobile phase was then filtered 
and degassed in a micro filter system (0.2 μm filter).  Mobile phase was stored in a 2000 
mL glass bottle at room temperature.  Additional mobile phase was prepared as required 
for the experiments performed in the thesis.  New mobile phase was prepared weekly or 
within a shorter time frame. 
 
3.3.2 HPLC Rinse Solution 
 
The HPLC rinse solution used in the thesis consisted of 65 % acetonitrile and 35 
% RO water.  The HPLC rinse solution was prepared by measuring 350 mL of RO water 
in a graduate cylinder, which was then transferred into a filter flask.  A 650 mL of 
acetonitrile was measured in a graduate cylinder and added to the water in the filter 
flask.  The HPLC rinse solution was then filtered and degassed in a micro filter system 
(0.2 μm filter).  The solution was stored in a 1000 mL glass bottle at room temperature.  
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Additional rinse solutions were prepared as required for the experiments performed in 
the thesis. 
 
3.3.3 THCA, THC, CBD, and CBN Standard Stock Solution  
 
Standard solutions required in the thesis were THC methanol solution purchased 
from Cerilliant, CBN methanol solution and CBD methanol solution, both purchased 
from the Sigma Aldrich.  THCA in methanol was obtained in house by preparative 
isolation from plant material as described below. All standard solutions were 1 mg/mL 
concentrations.   
A combined stock solution of THCA, THC, CBD, and CBN was prepared from 
1mg/mL standard methanol solutions.  Exactly 1 mL of each standard was combined 
into a 15 mL culture tube and taken to dryness at 35oC with the aid of a gentle stream of 
nitrogen.  The dried residue was reconstituted in 1 mL of methanol to give a combined 
stock solution with a concentration of 1 mg/mL for each compound.  This solution was 
stored at 4oC and used to prepare calibration standards as detailed below.   Additional 
standard stock solutions were prepared as required for the experiments performed in the 
thesis.  
 
3.3.4 Collection Of THCA-A 
 
THCA-A was collected from marihuana plant extracts since no commercial 
source of THCA was available.  The THCA solution was prepared using a method by 
Dautbegovic and Zhang.  The method is as follows:  Several marihuana plant methanolic 
extracts were combined to give approximately 100 mL total volume of extracts.  
Methanol was evaporated at 35°C under a gentle stream of nitrogen.  Residue that 
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remained at the bottom of a test tube was reconstituted in 10 mL of methanol.  The 
methanol solution was then injected onto HPLC and a peak corresponding to THCA-A 
was collected into a glass scintillation vial.  The collected solution was then evaporated 
at 35°C under gentle stream of nitrogen.  The residue remaining in a test tube was 
weighed and enough methanol was added to make 1 mg/mL THCA-A standard solution 
in methanol.  The THCA-A solution was shown to be 88-90% pure and was stored at 
4°C until further use. Purity was assessed by HPLC-UV where the total area for THCA 
was divided by the total area of all observed peaks. 
 
3.3.5 Working Solutions For THCA, THC, CBD and CBN Standard Curves 
 
The working solutions for THCA, THC, CBD, and CBN standard curve were 
prepared from THCA, THC, CBD, and CBN standard stock solution as described in 
section 3.3.3  The working solutions were prepared in Eppendorf 500 microcentrifuge 
tubes (1.5 mL vials).  Table 3.3 outlines the preparation of working solutions of THC, 
CBD, and CBN. 
Table 3.3 Preparation of the THCA,THC, CBD, and CBN working solutions for the standard curve 
Calibrator concentration  Volume of standard stock 
solution  
Volume of methanol  
200 μg/mL 100 μL of 1 mg/mL 400 μL 
100 μg/mL  200 μL of 200μg/mL 200 μL 
50 μg/mL 200 μL of 100μg/mL 200 μL 
25 μg/mL 200 μL of 50μg/mL 200 μL 
12.5 μg/mL 1000 μL of 25 μg/mL 200 μL 
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From each of the above working solutions, 75 μL was measured and placed in 
the microcentrifuge tube vials.  The unused portion of working solutions of THCA, THC 
CBD, and CBN were stored in the autosampler Robo® vials at 4oC.  Additional working 
solutions of THCA, THC, CBD, and CBN were prepared as required for the experiments 
in the thesis. 
 
3.3.6 Quality Control THCA, THC, CBD, and CBN Solutions 
 
The quality control (QC) solutions for THCA, THC, CBD, and CBN were 
prepared from THCA, THC, CBD, and CBN standard stock solution as described in 
section 3.3.3.  The quality control solutions were prepared in Eppendorf 500 
microcentrifuge tubes (1.5 mL vials).  Table 3.4 outlines the preparation of quality 
control solutions of THCA, THC, CBD, and CBN. 
 
Table 3.4 Preparation of the THCA,THC, CBD, and CBN quality control solutions 
Quality Control 
concentration
Volume of standard stock 
solution
Volume of methanol 
150 μg/mL 75 μL of 1 mg/mL 425 μL 
75 μg/mL 200 μL of 150 μg/mL 200 μL 
37.5 μg/mL 200 μL of 75μg/mL 200 μL 
 
Quality control solutions were stored in autosampler, Robo® vials with 400 μL 
of solution in each vial.   Quality control solutions were stored at 4oC and additional 
quality control solutions were prepared as required for experiments in the thesis. 
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On the day of the experiment, one vial of each quality control solution was 
removed from the fridge and 75 μL of each quality control was placed in the Eppendorf 
500 microcentrifuge tubes (1.5 mL vials).   
 
3.3.7 THCA-A Purity Check 
 
THCA-A collected from marihuana plant extracts (see section 3.3.4 for details) 
was evaluated for purity of THCA-A.  In order to assess the purity of the sample, 20 μL 
of THCA-A 1 mg/mL stock solution (see section 3.3.3) was injected onto the HPLC.  
The chromatogram that was produced showed several small peaks and a major peak 
representing THCA-A.  Areas under all peaks in the chromatogram were added together.  
The areas under all peaks added together divided the area under the THCA-A peak.  The 
result was then multiplied by one hundred in order to get percentage of THCA-A purity.  
In all samples, the purity was between 88-90%.  The area under the curve of THCA is 
1.1 times greater consistently than the area of THC for same given concentration.  This 
means that THCA gives a slightly stronger response by the UV detector then THC. 
 
3.3.8 Precision and Accuracy 
 
Precision and accuracy were evaluated by analyzing standards and quality 
controls in replicates of five or ten depending on the experiment.    Standards were made 
as per section 3.3.3 and analyzed in replicates of two with every new experiment.  
Quality control samples were analyzed in replicates of two in every experiment to 
further demonstrate accuracy and precision of the HPLC method. 
 
  31
 
3.4 Analytical Method 
3.4.1 Extraction of Marihuana Material 
 
The contents of each plant material sample (approximately 5 g) were ground to a 
fine homogeneous powder using a coffee bean grinder (ground at full speed for 1 minute 
followed by a meticulous cleaning of the grinder using a combination of water and 
methanol). A representative sample of approximately 5 mg of plant material (weight was 
recorded accurately) of each plant sample was weighed in a 15 mL disposable glass 
tube.  Methanol (3mL) was added to each sample, the glass tube containing plant sample 
and methanol was capped and placed on IKA-Vibrax shaker at speed 1000.  The samples 
were shaken for 30 minutes after which methanol was removed to a 20 mL scintillation 
vial and capped. The procedure was repeated one more time for each unknown sample 
resulting in 6 mL total of methanol extract in each instance.  The unknown samples were 
stored at 4o C until analysis.   
On the day of the analysis, 50 μL of each unknown was placed into 1.5 mL 
microcentrifuge tube vials and were injected onto the HPLC. 
 
3.5 Combustion Of Marihuana Material 
 
3.5.1 Pipe Method 
 
A pipe was attached to the 3M SPE cartridge that was then attached to a vacuum 
pump (see figure 4.3).  The 5 mg sample was then placed in the mesh in the pipe and the 
vacuum was switched on.  The cannabis was then ignited using a butane lighter and 
combusted to a white ash.  The SPE cartridge was extracted using 1 mL of methanol and 
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the extract was analyzed on HPLC-UV to determine the cannabinoids profile and 
recovery from the original sample.  This setup worked very well as large amounts of 
THC were seen on the HPLC-UV as well as quantifiable amounts of CBD, CBN and 
CBC.    
 
3.5.2 Test Tube Method 
 
A 5 mg sample of marihuana material was weighed and stored in capped test 
tubes until needed.  When it was time to analyze the sample, it was transferred to the 
smoking device and combusted.  This machine worked by placing the sample to be 
ignited in the bottom of a test tube (see figure 4.4).  A small piece of flexible hose was 
then attached to the test tube that had an SPE cartridge attached to it.  The vacuum pump 
was then attached to the base of the SPE cartridge.  The sample was heated using a 
Bunsen burner or butane lighter.  Combustion could clearly be seen as smoke began to 
form inside the test tube.  At this point, the vacuum was turned on and the smoke was 
pulled out of the test tube and deposited on the SPE cartridge.  Once the sample showed 
only ash remaining, the vacuum was turned off.  The SPE cartridge was then extracted 
with 1 mL of methanol on the vacuum extraction manifold.  At the same time, the test 
tube had 1 mL of methanol added to it and was capped and then shaken on a vibrax 
shaker at speed 1000 for 10 minutes.  After completion of shaking, the sample was 
filtered and placed in storage tube so it could be analyzed.   Each extract was then 
analyzed and the total amounts of each analyte found in the test tube and the SPE 
cartridge were added together to give the total cannabinoid profile. 
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3.5.3 Oven Method 
 
A sample of cannabis plant with a known concentration of THCA was placed 
inside a glass test tube and then capped with a heat stable screw cap.  The experiments 
were then performed at varying temperatures and time duration.  The test tubes were 
then removed from the oven and allowed to cool.   After cooling, 3 mL of methanol was 
added to each test tube and shaken on a vibrax shaker speed 1000 for ten minutes.  The 
methanol extract was then filtered and placed inside a suitable vial that could then be 
analyzed under HPLC-UV and/or HPLC-MS/MS. 
 
3.5.4 Measurement of Temperature of Marihuana Cigarette 
 
A sample of cannabis plant was placed inside one of the pipes and the 
temperature of the lit portion of marihuana was measured using a Cole Parmer 
Thermosense digital thermometer and probe. 
 
3.5.5 Measurement of Vacuum Used to Simulate Drawing of Combusted 
Marihuana Smoke 
 
A vacuum gauge was used to record the vacuum at which the air was being 
drawn through the smoking machine’s orifice. 
 
3.6 HPLC Analytical Method 
HPLC consisted of the parts described in section 3.2.0 and was maintained as 
required throughout the experimental time for the thesis.  The column was installed and 
conditioned according to the manufacturers instructions.  Mobile phase was prepared as 
described in detail in section 3.3.1 and set at isocratic flow rate of 1.5 mL/min.  All 
  34
experiments were performed at room temperature.  The length of analysis of each 
individual sample was twenty minutes.  The UV detector was set at a wavelength of 
230nm.  All injections were performed by the autosampler and were set at 20 μL.  Data 
were acquired and processed by the peak integrations using the Waters Empower 
chromatography software.  All necessary dilution factors were applied in order to report 
the concentrations of each analyte in terms of gram percent taking into account the 
original weight of tissue extracted. 
  
3.7 LC-MS-MS Analytical Method 
For the liquid chromatography tandem mass spectrometry (LC-MS-MS) method, 
the column was installed and conditioned according to the manufacturers instructions.  
The column used was XTerra® MSC18 3.5 μm (2.1mm x 100 mm).  The mobile phase 
consisted of 70 % acetonitrile with 30 % aqueous 0.1 % formic acid solution.  The flow 
rate was set at 0.25mL/min.  The detector used for the LC-MS-MS method was 
Micromass Quatro Ultima tandem mass spectrometer. The software version was 
MassLynx 3.5.  All injections were performed by the auto-sampler and were set at 5 μL. 
The positive ion model used for THC, CBD, CBN, CBC, CBG, and THCA-A is outlined 
in table 3.5.  
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Table 3.5 Positive ion model used for THC, CBD, CBN, CBC, CBG, and THCA-A 
Analyte Parent ion 
(m/z) 
Daughter 
ion (m/z) 
D well 
(sec.) 
Cone     
(E lab) 
Collision 
energy  
(E lab) 
Retention 
(min) 
CBN 311.4 223.2 0.3 30 20 9.31 
THC 315.2 193.2 0.3 30 20 11.82 
CBC 315.2 193.2 0.3 30 20 16.14 
CBD 315.3 123.3 0.3 30 30 5.73 
CBG 317.4 193.2 0.3 30 15 5.48 
THCA-A 359.4 219.2 0.3 30 30 16.95 
 
The peak integrations were acquired and processed using the Waters Empower 
chromatography software.  All the necessary dilution factors were applied to report the 
concentration of each analyte in terms of gram percent taking into account the original 
weight of tissue extracted 
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4 RESULTS AND DISCUSSION 
 
4.1 Smoking Machine Analysis 
4.1.1 Background 
 
The cannabinoid profile of combusted cannabis is important since it more truly 
represents the components available for absorption in human.  To date, much of the 
analytical work carried out on cannabinoids has been done by GC and therefore the 
resulting profile may be considered to represent the thermally decomposed profile of 
plant tissue extract.  Whether such a profile is identical to the chemical profile obtained 
during clandestine combustion such as that used in the delivery of marihuana is not 
clear.  In this regard, the specific thermal conversion of THCA to THC has been 
considered quantitative during GC analysis but whether this is the case during 
clandestine combustion has not been reported.  Therefore, an experiment was designed 
to examine both qualitatively and quantitatively the compounds found in marihuana 
plant tissue after combustion has taken place and furthermore, to compare these to the 
original chromatographic profile of the raw plant.  Quantitative analysis of cannabis 
combustion smoke is fraught with some difficulties.  First the system needs to mimic 
techniques used in the field and yet capture all of the smoke.  A number of model 
devices were employed along with actual devices used in the field. 
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4.1.2 The Smoking Machines 
 
Four different smoking machines were employed.  Each of these is discussed in 
the following sections with a brief comment related to the apparent suitability of each set 
up.  For those machines that worked well, a more in depth study was undertaken. 
 
4.1.2.1 Smoking Machine #1 
 
The first smoking machine followed the preconceived idea that if you ignited the 
sample and then pulled the smoke through a suitable solvent such as methanol, the 
cannabinoids would dissolve in the methanol and the methanol could be analyzed using 
HPLC-UV.  To test this technique a vaporizer device was employed (see figure 4.1).  
This device represents a closed system that has a controllable intake and exhaust line.  
By connecting the exhaust line in such a way that all of the exhaust must bubble through 
a methanol trap, it should be possible to extract cannabinoids present in the smoke into 
methanol.  A 50 mL syringe was used to draw smoke through the exhaust and into the 
trap (see figure 4.1).  A chromatographic profile could then be obtained through HPLC-
UV (see section 3.6.0) analysis of the methanol in the trap.   
No cannabinoids were found on the HPLC-UV chromatogram which means that they 
were not dissolving in the methanol as it had been hoped.  Furthermore, analyzing the 
inside of the vaporizer by rinsing it repeatedly with methanol showed that some of the 
cannabinoids had adhered to the inside of the glass enclosure, as a large CBN peak was 
shown on the HPLC-UV chromatogram.  Why only the CBN peak was in abundance 
relative to the other major cannabinoids peaks typically seen is unclear. 
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Figure 4.1 Smoking Machine #1 
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4.1.2.2 Smoking Machine #2 
 
The second smoking machine that was employed involved the use of a gas 
sampling bulb.  The gas sampling bulb is a circular glass vial 750 mL in capacity.  At 
either end of it is two valves that can be opened and closed and are airtight when in the 
closed position.  In the middle of the bulb is a one way syringe valve that can be used to 
sample the vapor inside the vesicle (see figure 4.2).  The idea behind using the gas 
sampling vesicle was that by creating a vacuum inside of the bulb by using a vacuum 
pump, a negative pressure zone would develop.  This negative pressure zone could then 
be used to draw a substance into the vesicle by opening one of the two valves at either 
end of the vesicle.  The idea is that one could ignite a sample of cannabis plant and have 
the sample orifice connected to the gas sampling vesicle.  Once the valve was open, the 
negative pressure would draw the combusted cannabis plant into the gas sampling 
vesicle which could then be rinsed with methanol and analyzed using HPLC-UV and 
HPLC-MS.   
The biggest problem with this device was creating a suitable orifice and 
connecting it to the gas sampling vesicle so no sample would be lost to the external 
environment.  The orifice created was milled with a drill press using brass fittings.  A 
suitable fine mesh was then inserted into the orifice to hold the cannabis sample and a 
compression fitting was used to connect the brass pipe to the gas-sampling vesicle.  The 
gas-sampling vesicle was then evacuated using the vacuum pump for ten minutes.  At 
this point, the sample in the orifice was ignited, and the vacuum valve was opened 
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slightly to create a negative pressure zone and the smoke was drawn into the gas 
sampling vesicle.   
 Results indicated that it was impossible to evacuate the gas sampling vesicle 
enough to ensure a sustained vacuum.  Without a sustained vacuum, the smoke escaped 
to atmosphere.  Pressuring the vesicle for even 30 minutes still resulted in a vacuum that 
only lasting a few seconds.  The problem is most likely the failure of the valve to control 
the vacuum at low levels.  Hence, when the valve was opened, a large vacuum was 
created but only for a short period of time until atmospheric conditions were re-
established.    
 Analyzing the inside of the gas sampling vesicle by repeated rinsing with 
methanol showed some interesting results.  First of all, there was a large THC peak seen 
under HPLC-UV analysis with smaller peaks for CBD and CBN also showing up.  The 
problem was too much of the combusted sample was escaping to atmosphere.  This 
meant that although qualitatively cannabinoids were observed, quantitatively, their 
levels were far less then the plant’s original THCA concentration assuming you had a 
100% quantitative conversion to THC.  This was expected as stated above:  there was 
not enough sustained vacuum to move the combusted cannabinoids to inside the gas 
sampling vesicle before the entire cannabis sample was burned. 
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4.1.2.3 Smoking Machine #3 
 
The third smoking machine that was devised provided a constant source of 
vacuum that could be user controllable for a specified length of time.  Through the use 
of a rotary vacuum pump a constant vacuum could be created. So as to not simply lose 
all of the smoke and its contents to the vacuum pump oil, a “trap” was necessary 
between the combustion product and the vacuum pump.  Consequently a medium was 
required that  could reliably trap and contain all analytes with close to 100% recovery, 
which would ensure that the vacuum pump was not pulling everything past the media.  
Solid phase extraction cartridges offer characteristics similar to the columns that were 
being used to separate the cannabinoids in the HPLC-UV system and the HPLC-MS 
system.   The first SPE cartridge used was a 3M Empore High Performance Extraction 
disk cartridge that had C18 standard density packing and was 7mm x 3mL in size.  
Another brass fitting was constructed that could have a fine mesh inserted into it to hold 
the sample.  The brass sample container was then attached to an SPE cartridge that was 
then attached to a vacuum pump.  The sample was then placed in the brass pipe and the 
vacuum was switched on  (see figure 4.3).  The cannabis was then ignited using a butane 
lighter and combusted to a nice white ash.  The SPE cartridge was extracted using 
methanol and the extract was analyzed on HPLC-UV to determine the cannabinoids 
profile and recovery from the original sample.  This setup worked very well as large 
amounts of THC were seen on the HPLC-UV as well as quantifiable amounts of CBD, 
CBN and CBC.  It was decided at this point that this setup worked quite well and further 
investigations using this setup should be pursued.   
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Figure 4.3 Smoking Machine #3 
3M SPE Cartridge Vacuum Pump Pipe 
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4.1.2.4 Smoking Machine #4 
 
Smoking machine #3 worked very well as far as mimicking fairly accurately the actual 
process of smoking a cigarette.  The problem with it was that some of the smoke was 
lost to atmosphere and also analyzing the sample holding area was a tedious process.  
Therefore, another idea was proposed that would follow the same basic principle of 
smoking machine #3 but also allow for the absolute measurement of all smoke produced 
and also an easier means to analyze the sample holding area.  This would allow a more 
quantitative analysis of the cannabinoids since, in theory, it may be possible to not loose 
any sample after combustion.   This machine worked by placing the sample to be ignited 
in the bottom of a test tube.  A small piece of flexible hose was then attached to the test 
tube that had an SPE cartridge attached to it.  The vacuum pump was then attached to 
the base of the SPE cartridge.  The sample was heated using a Bunsen burner or butane 
lighter.  Combustion could clearly be seen as smoke began to form inside the test tube.  
At this point, the vacuum was turned on and the smoke was pulled out of the test tube 
and deposited on the SPE cartridge.  Once the sample showed only ash remaining, the 
vacuum was turned off.  The SPE cartridge was then extracted with 1 mL of methanol 
on the vacuum extraction manifold.  At the same time, the test tube had 1 mL of 
methanol added to it and was capped and then mixed on a vibrax shaker at speed setting 
1000 for 10 minutes.  The sample was filtered and placed in storage tube so it could be 
analyzed by HPLC-UV (see method 3.6.0).   
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Figure 4.4 Smoking Machine #4
3M SPE Vacuum Pump 
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4.1.2.5 Other Devices Used in the Analytical Process to Determine the 
Combustion Profile of Cannabis Sativa Plant 
 
To further verify the effect of heat on cannabis plant tissue, a number of experiments 
were carried out looking at the effect varying amounts of heat and various temperatures 
had on the cannabinoid profile of marihuana.  In order to do this, a convection oven 
from an HP 5790 gas chromatograph capable of temperature programming was used.   A 
sample of cannabis plant with a known concentration of THCA was placed inside a glass 
test tube and then capped with a heat stable screw cap.  The experiments were then 
performed at varying temperatures from ambient to 250°C and time duration of zero to 
thirty minutes  The test tubes were then removed from the oven and allowed to cool.   
After cooling, 3 mL of methanol was added to each test tube and mixed on a vibrax 
shaker speed setting 1000 for ten minutes.  The methanol extract was then filtered and 
placed inside a suitable vial that could then be analyzed under HPLC-UV and/or HPLC-
MS/MS. 
 
4.2 Intra And Inter – Assay Precision And Accuracy For THC, CBD, CBN And 
THCA 
 
The HPLC-UV method used to quantify and analyze qualitatively the 
cannabinoids of interest was validated previously (Dautbegovic et al, 2003).  However, 
it was felt important to re-validate the results of this method since it employs a much 
smaller sample size (5mg versus 100mg) and was to be used by a different analyst.   
A re-validation of the original method was undertaken to demonstrate inter-assay 
variability.  The inter-assay % CV and observed % difference from nominal could be 
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used to attest to the precision and accuracy of the method since it demonstrates assay 
performance on different days by an alternate analyst. Table 4.1 shows the %CV was 
less than 4.5 % across the range of concentrations 12.5 µg/mL to 200 µg/mL for CBD.  
Similarly for CBN (Table 4.2) the inter-assay %CV was less than 5.47 % across the 
calibration range.  THC (Table 4.3) demonstrated 6.95 % or less variation between days 
of analysis across the calibration range.  THCA %CV inter-assay variation was no 
greater then 4.49% across the calibration range (Table 4.4). 
     The quality control samples included duplicates at the low concentration (37.5 
μg/mL), mid-point concentration (75 μg/mL) and at a high concentration (150 μg/mL).  
The quality control (QC) samples analyzed with these calibrators demonstrated that 
37/38 of QC’s at all concentrations had a bias (% difference from actual concentration) 
of less than ±15 % for CBD (table 4.5), CBN (table 4.6), THC (table 4.7) and THCA 
(table 4.8).  The only problematic QC was one of the two mid point concentrations on 
day 1.  It consistently gave a value of approximately 16% difference for CBD, CBN, 
THC and THCA.  Furthermore the %CV of the QC’s across all days for each analyte at 
all concentration levels was always less then 5%.   
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Table 4.1 Revalidation of HPLC-UV method for CBD Standard 
REVALIDATION OF HPLC-UV METHOD 
CBD OBSERVED CONCENTRATION FOR THE FOLLOWING STANDARDS µg/mL 
             
DAY 12.5 % diff 25 % diff 50 % diff 100 % diff 200 % diff 
1 * * * * * * * * * * 
  12.73 1.81 24.90 -0.38 50.53 1.05 98.72 -1.28 200.25 0.13 
             
2 11.67 -6.63 24.37 -2.52 51.07 2.15 105.34 5.34 204.18 2.09 
  11.31 -9.51 24.11 -3.55 49.58 -0.84 100.12 0.12 193.24 -3.38 
             
3 12.29 -1.70 26.78 7.12 52.07 4.14 106.61 6.61 * * 
  12.57 0.54 23.94 -4.24 46.94 -6.13 93.52 -6.48 190.04 -4.98 
             
4 13.04 4.33 24.23 -3.09 48.90 -2.21 100.83 0.83 196.39 -1.80 
  13.15 5.20 24.73 -1.10 49.48 -1.04 102.14 2.14 203.61 1.80 
             
5 11.85 -5.23 24.70 -1.22 49.55 -0.91 100.21 0.21 196.78 -1.61 
  11.99 -4.10 25.25 0.98 50.93 1.85 101.58 1.58 202.51 1.26 
             
6 11.85 -5.23 24.70 -1.22 49.55 -0.91 100.21 0.21 196.78 -1.61 
  11.99 -4.10 25.25 0.98 50.93 1.85 101.58 1.58 202.51 1.26 
             
7 11.85 -5.23 24.70 -1.22 49.55 -0.91 100.21 0.21 196.78 -1.61 
  11.99 -4.10 25.25 0.98 50.93 1.85 101.58 1.58 202.51 1.26 
                      
MEAN 12.17  24.84  50.00  100.97  198.80   
SD 0.55  0.72  1.29  3.11  4.48   
%CV 4.50   2.91   2.58   3.08   2.26   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Datum for day 1 was discarded due to a problem with the autosampler injecting the 
wrong volume of sample.  Datum for day 3 at 200 µg/mL was discarded due to 
contamination. 
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Table 4.2 Revalidation of HPLC-UV method for CBN Standard 
REVALIDATION OF HPLC-UV METHOD 
CBN OBSERVED CONCENTRATION FOR THE FOLLOWING STANDARDS µg/mL 
             
RUN # 12.5 % diff 25 % diff 50 % diff 100 % diff 200 % diff 
1 * * * * * * * * * * 
  10.78 -13.79 23.18 -7.28 48.65 -2.71 98.12 -1.88 198.34 -0.83 
             
2 10.69 -14.52 24.35 -2.61 51.56 3.11 106.06 6.06 203.86 1.93 
  10.91 -12.71 23.56 -5.76 50.28 0.55 101.36 1.36 192.65 -3.67 
             
3 12.35 -1.18 26.56 6.24 51.97 3.95 106.58 6.58 * * 
  12.39 -0.88 24.44 -2.23 47.08 -5.84 93.82 -6.18 187.52 -6.24 
             
4 12.43 -0.56 23.93 -4.28 49.10 -1.80 101.50 1.50 196.18 -1.91 
  12.39 -0.92 24.52 -1.93 49.97 -0.06 103.24 3.24 202.27 1.14 
             
5 11.30 -9.62 24.44 -2.23 50.00 -0.01 101.31 1.31 196.34 -1.83 
  11.46 -8.32 25.08 0.32 50.73 1.47 102.38 2.38 201.55 0.78 
             
6 11.30 -9.62 24.44 -2.23 50.00 -0.01 101.31 1.31 196.34 -1.83 
  11.46 -8.32 25.08 0.32 50.73 1.47 102.38 2.38 201.55 0.78 
             
7 11.30 -9.62 24.44 -2.23 50.00 -0.01 101.31 1.31 196.34 -1.83 
  11.46 -8.32 25.08 0.32 50.73 1.47 102.38 2.38 201.55 0.78 
                      
MEAN 11.55  24.55  50.06  101.67  197.87   
SD 0.63  0.83  1.26  3.19  4.68   
%CV 5.47   3.37   2.52   3.14   2.36   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Datum for day 1 was discarded due to a problem with the autosampler injecting the 
wrong volume of sample.  Datum for day 3 at 200 µg/mL was discarded due to 
contamination. 
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Table 4.3 Revalidation of HPLC-UV method for THC Standard 
REVALIDATION OF HPLC-UV METHOD 
THC OBSERVED CONCENTRATION FOR THE FOLLOWING STANDARDS µg/mL 
             
RUN # 12.5 % diff 25 % diff 50 % diff 100 % diff 200 % diff 
1 * * * * * * * * * * 
  13.66 9.28 25.16 0.62 49.68 -0.64 97.59 -2.41 200.70 0.35 
             
2 10.86 -13.09 22.40 -10.40 46.39 -7.23 95.24 -4.76 186.90 -6.55 
  11.13 -10.97 21.94 -12.23 45.01 -9.98 91.12 -8.88 176.67 -11.67 
             
3 12.76 2.09 26.34 5.36 51.42 2.83 107.31 7.31 * * 
  13.10 4.80 24.03 -3.90 46.45 -7.11 93.46 -6.54 193.31 -3.35 
             
4 13.25 6.02 24.40 -2.40 48.09 -3.81 99.48 -0.52 196.88 -1.56 
  14.06 12.49 25.19 0.75 49.66 -0.69 101.22 1.22 204.28 2.14 
             
5 12.59 0.73 24.82 -0.71 48.82 -2.36 98.82 -1.18 196.53 -1.74 
  13.02 4.14 25.62 2.47 50.44 0.88 100.76 0.76 204.18 2.09 
             
6 12.59 0.73 24.82 -0.71 48.82 -2.36 98.82 -1.18 196.53 -1.74 
  13.02 4.14 25.62 2.47 50.44 0.88 100.76 0.76 204.18 2.09 
             
7 12.59 0.73 24.82 -0.71 48.82 -2.36 98.82 -1.18 196.53 -1.74 
  13.02 4.14 25.62 2.47 50.44 0.88 100.76 0.76 204.18 2.09 
                      
MEAN 12.74  24.67  48.81  98.78  196.74   
SD 0.88  1.26  1.88  4.00  8.26   
%CV 6.95   5.12   3.86   4.05   4.20   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Datum for day 1 was discarded due to a problem with the autosampler injecting the 
wrong volume of sample.  Datum for day 3 at 200 µg/mL was discarded due to 
contamination. 
 
 
  51
 
Table 4.4 Revalidation of HPLC-UV method for THCA Standard 
REVALIDATION OF HPLC-UV METHOD 
THCA OBSERVED CONCENTRATION FOR THE FOLLOWING STANDARDS µg/mL 
             
RUN # 12.5 % diff 25 % diff 50 % diff 100 % diff 200 % diff 
1 * * * * * * * * * * 
  12.53 0.23 25.06 0.25 50.61 1.21 99.05 -0.95 200.45 0.22 
             
2 11.34 -9.28 25.16 0.62 50.74 1.48 104.72 4.72 206.10 3.05 
  11.30 -9.64 24.38 -2.48 50.09 0.18 99.50 -0.50 192.02 -3.99 
             
3 12.32 -1.44 26.89 7.56 51.34 2.69 107.38 7.38 * * 
  12.64 1.14 24.01 -3.98 47.11 -5.78 92.84 -7.16 190.53 -4.74 
             
4 12.78 2.23 23.83 -4.66 49.04 -1.92 100.89 0.89 197.14 -1.43 
  13.29 6.31 24.52 -1.93 49.19 -1.62 102.55 2.55 201.60 0.80 
             
5 12.60 0.83 24.81 -0.75 48.92 -2.16 98.51 -1.49 195.99 -2.00 
  12.75 2.00 25.94 3.75 50.42 0.84 101.04 1.04 204.89 2.45 
             
6 12.60 0.83 24.81 -0.75 48.92 -2.16 98.51 -1.49 195.99 -2.00 
  12.75 2.00 25.94 3.75 50.42 0.84 101.04 1.04 204.89 2.45 
             
7 12.60 0.83 24.81 -0.75 48.92 -2.16 98.51 -1.49 195.99 -2.00 
  12.75 2.00 25.94 3.75 50.42 0.84 101.04 1.04 204.89 2.45 
                      
MEAN 12.48  25.08  49.70  100.43  199.21   
SD 0.56  0.88  1.14  3.46  5.34   
%CV 4.49   3.49   2.29   3.45   2.68   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Datum for day 1 was discarded due to a problem with the autosampler injecting the 
wrong volume of sample.  Datum for day 3 at 200 µg/mL was discarded due to 
contamination. 
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Table 4.5 Revalidation of HPLC-UV method for CBD Quality Controls 
REVALIDATION OF HPLC-UV METHOD 
CBD OBSERVED CONCENTRATION FOR THE FOLLOWING QUALITY CONTROLS 
         
DAY QC1 37.5 µg/mL % diff QC2 75 µg/mL % diff 150 µg/mL % diff 
1 37.78 0.74 78.14 4.19 154.12 2.75 
  42.78 14.07 87.74 16.99 168.59 12.39 
         
2 *  82.46 9.95 160.90 7.27 
  *  82.48 9.97 160.41 6.94 
         
3 *  84.06 12.08 148.98 -0.68 
  *  85.14 13.52 147.24 -1.84 
         
4 38.51 2.68 78.95 5.26 160.56 7.04 
  38.99 3.98 80.56 7.41 159.84 6.56 
         
5 39.06 4.16 79.32 5.75 155.93 3.95 
  38.25 2.00 77.87 3.83 153.67 2.45 
         
6 39.06 4.16 79.32 5.75 155.93 3.95 
  38.25 2.00 77.87 3.83 153.67 2.45 
         
7 39.06 4.16 79.32 5.75 155.93 3.95 
  38.25 2.00 77.87 3.83 153.67 2.45 
              
MEAN 39.13   81.00   156.56   
SD 1.42  3.14  5.59   
%CV 3.62   3.88   3.57   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Day 2 and Day 3 at the 37.5 µg/mL quality control amount were discarded due to a 
problem with the autosampler injecting the wrong volume of sample. 
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Table 4.6 Revalidation of HPLC-UV method for CBN Quality Controls 
REVALIDATION OF HPLC-UV METHOD 
CBN OBSERVED CONCENTRATION FOR THE FOLLOWING QUALITY CONTROLS 
         
DAY QC1 37.5 µg/mL % diff QC2 75 µg/mL % diff 150 µg/mL % diff 
1 36.26 -3.31 76.50 2.00 152.69 1.80 
  41.72 11.26 87.13 16.17 167.59 11.73 
         
2 *  83.13 10.84 161.52 7.68 
  *  82.54 10.06 161.32 7.55 
         
3 *  84.45 12.60 147.33 -1.78 
  *  84.98 13.31 146.66 -2.23 
         
4 38.76 3.35 80.02 6.70 160.93 7.28 
  39.28 4.75 81.64 8.85 159.98 6.65 
         
5 38.96 3.88 80.29 7.06 156.41 4.27 
  38.39 2.38 78.80 5.06 154.67 3.12 
         
6 38.96 3.88 80.29 7.06 156.41 4.27 
  38.39 2.38 78.80 5.06 154.67 3.12 
         
7 38.96 3.88 80.29 7.06 156.41 4.27 
  38.39 2.38 78.80 5.06 154.67 3.12 
              
MEAN 39.09   81.63   156.81   
SD 1.04  2.65  5.72   
%CV 2.65   3.25   3.65   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Day 2 and Day 3 at the 37.5 µg/mL quality control amount were discarded due to a 
problem with the autosampler injecting the wrong volume of sample. 
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Table 4.7 Revalidation of HPLC-UV method for THC Quality Controls 
REVALIDATION OF HPLC-UV METHOD 
THC OBSERVED CONCENTRATION FOR THE FOLLOWING QUALITY CONTROLS 
         
DAY QC1 37.5 µg/mL % diff QC2 75 µg/mL % diff 150 µg/mL % diff 
1 37.73 0.63 77.12 2.83 153.25 2.17 
  42.31 12.83 87.06 16.09 168.21 12.14 
         
2 *  74.86 -0.19 146.67 -2.22 
  *  74.35 -0.86 146.39 -2.41 
         
3 *  83.52 11.37 149.25 -0.50 
  *  84.92 13.22 149.28 -0.48 
         
4 38.33 2.23 77.62 3.50 158.92 5.95 
  38.66 3.09 79.03 5.38 159.33 6.22 
         
5 38.51 2.69 78.09 4.12 154.55 3.03 
  37.78 0.74 76.59 2.12 152.91 1.94 
         
6 38.51 2.69 78.09 4.12 154.55 3.03 
  37.78 0.74 76.59 2.12 152.91 1.94 
         
7 38.51 2.69 78.09 4.12 154.55 3.03 
  37.78 0.74 76.59 2.12 152.91 1.94 
              
MEAN 38.68   78.88   153.88   
SD 1.41  3.88  5.88   
%CV 3.64   4.92   3.82   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Day 2 and Day 3 at the 37.5 µg/mL quality control amount were discarded due to a 
problem with the autosampler injecting the wrong volume of sample. 
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Table 4.8 Revalidation of HPLC-UV method for THCA Quality Controls 
REVALIDATION OF HPLC-UV METHOD 
THCA OBSERVED CONCENTRATION FOR THE FOLLOWING QUALITY CONTROLS 
         
DAY QC1 37.5 µg/mL % diff QC2 75 µg/mL % diff 150 µg/mL % diff 
1 36.86 -1.71 76.87 2.49 153.78 2.52 
  42.19 12.51 88.74 18.32 168.91 12.61 
         
2 *  83.62 11.49 161.92 7.95 
  *  82.64 10.19 159.20 6.13 
         
3 *  83.84 11.79 148.58 -0.94 
  *  84.17 12.22 142.24 -5.18 
         
4 38.35 2.26 79.31 5.75 160.43 6.96 
  39.40 5.07 81.24 8.31 155.13 3.42 
         
5 39.40 5.06 78.96 5.28 154.41 2.94 
  37.91 1.10 76.58 2.10 152.22 1.48 
         
6 39.40 5.06 78.96 5.28 154.41 2.94 
  37.91 1.10 76.58 2.10 152.22 1.48 
         
7 39.40 5.06 78.96 5.28 154.41 2.94 
  37.91 1.10 76.58 2.10 152.22 1.48 
              
MEAN 39.10   80.78   155.10   
SD 1.36  3.66  6.56   
%CV 3.47   4.53   4.23   
* All data was analyzed in replicates of two for each concentration over a 7 day period. 
** Day 2 and Day 3 at the 37.5 µg/mL quality control amount were discarded due to a 
problem with the autosampler injecting the wrong volume of sample. 
 
 
 
 
4.3 Solid Phase Extraction Recovery 
The first experiment carried out was to determine the % recovery of the 3M C18 
SPE cartridge using liquid standards.  This was accomplished by taking standards of 
CBD, CBN, THC and THCA and running them through the cartridge.  The cartridge was 
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mounted on a Waters vacuum filtration extraction system capable of extracting 20 
samples at a time.  A sample size of 1 mL was injected onto the cartridge with a 
concentration of 100 µg/mL for each standard.  After the samples had stopped flowing 
through the cartridge, the vacuum system was turned on and stayed on until a pressure –
20 mm Hg was obtained.  Clean test tubes were placed underneath the cartridges and the 
methanol was collected and the resulting eluent was analyzed.  Each standard was 
reconstituted in 20% methanol / water and then extracted using 100% methanol.  The 
reason for this was cannabinoids dissolve so well in methanol that it was hard to get 
them to adhere to the column if the solvent contained too much methanol.  Less then 
20% methanol resulted in precipitation and clogging up the SPE cartridge.  Each 
standard was analyzed in replicates of 5.  Table 4.9 shows THC standard at a 
concentration of 100 µg/mL.  It can be seen that the average concentration recovered 
was 88.98 µg/mL with a %CV of 3.09.  Table 4.10 shows CBD standard at a 
concentration of 100 µg/mL.  It can be seen that the average concentration recovered 
was 90.18 µg/mL with a %CV of 2.56.  Table 4.11 shows CBN standard at a 
concentration of 100 µg/mL.  It can be seen that the average concentration recovered 
was 88.06 µg/mL with a %CV of 2.46.  Lastly, Table 4.12 shows THCA standard at a 
concentration of 100 µg/mL.  It can be seen that the average concentration recovered 
was 88.58 µg/mL with a %CV of 2.44.  
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Table 4.9 Recovery of THC using 3M C18 SPE cartridges, concentration of THC was 100µg/mL 
 
SAMPLE CONCENTRATION 
THC RECOVERED 
1 89.3 
2 88.8 
3 89.5 
4 84.8 
5 92.5 
AVERAGE 88.98 
SD 2.75 
%CV 3.09 
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Table 4.10 Recovery of CBD using 3M C18 SPE cartridges, concentration of CBD was 100 µg/mL 
 
SAMPLE CONCENTRATION 
CBD RECOVERED 
1 92.4 
2 92.8 
3 87.5 
4 88.9 
5 89.3 
AVERAGE 90.18 
SD 2.31 
%CV 2.56 
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Table 4.11 Recovery of CBN using 3M C18 SPE cartridges, concentration of CBN was 100 µg/mL 
 
SAMPLE CONCENTRATION 
CBN RECOVERED 
1 89.4 
2 84.8 
3 88.5 
4 87.2 
5 90.4 
AVERAGE 88.06 
SD 2.16 
%CV 2.46 
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Table 4.12 Recovery of THCA using 3M C18 SPE cartridges, concentration of THCA was 100 
µg/mL 
 
SAMPLE CONCENTRATION 
THCA RECOVERED 
1 88.8 
2 89.3 
3 85.6 
4 91.5 
5 87.7 
AVERAGE 88.58 
SD 2.16 
%CV 2.44 
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4.4 Cannabis Sativa Cannabinoids HPLC-MS-MS Profiles 
 In order to evaluate the cannibinoid profile of a typical marihuana plant, the analytical 
procedure as stated in section 3.7.0 was carried out on standards of CBD, CBN, THC, 
THCA and CBC.  This was necessary to determine the mass spectral characteristics of 
each cannabinoid under MS and MS/MS conditions.  The reason for doing this was to 
create a known ion chromatogram library that could be used as a reference later on when 
looking at the combustion products of cannabis. 
 Figure 4.5 is the full scanning ion chromatogram for CBD.  It can clearly be seen 
that the base peak and the molecular ion is seen at a mass of 315.  The product ion scan 
of the 315 mass is shown in figure 4.6.  It shows a large peak at 123 and a smaller peak 
at 193 mass.   
 Figure 4.7 is the full scanning ion chromatogram for CBN.  It can be seen that 
the base peak and molecular ion is seen at a mass of 311.  The product ion scan of the 
311 mass is shown in figure 4.8.  It shows a predominant peak at mass 223. 
 Figure 4.9 is the full scanning ion chromatogram for THC.  It can be seen that 
the base peak and molecular ion is seen at a mass of 315.  It is notable that the molecular 
weight for CBD and THC is the same.  The only difference between the molecules is a 
ring opening on CDB (see figure 1.4).  The product ion scan of the 315 mass is shown in 
figure 4.10.  It shows a base peak at mass 193 with smaller peaks at 123, 135 and 259. 
 Figure 4.11 is the full scanning ion chromatogram for THCA.  It can be seen that 
the base peak is seen at a mass of 391 and the molecular ion is seen at a mass of 359.  
Under electrospray positive mode, it is difficult to add a [H+] ion to the THCA molecule 
as under low pH conditions, the acidic site on the THCA molecule will already be 
protonated from the acidic mobile phase.  As a result of this, the base peak differs from 
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the molecular ion under electrospray positive conditions.  The product ion scan of the 
359 mass is shown in figure 4.12.  It shows a predominant peak at mass 219 and a 
smaller peak at mass 341. 
 Figure 4.13 is the full scanning ion chromatogram for CBC.  It can be seen that 
the base peak and molecular ion is seen at a mass of 315.  The product ion scan of the 
315 mass is shown in figure 4.14.  It shows a predominant peak at mass 193. 
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Figure 4.5 CBD full scanning Ion Chromatogram from Micromass Ultima Triple Quadrapole Mass 
Spectrometer using electrospray positive ion mode and using analytical procedure stated in section 
3.7.0 
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Figure 4.6 CBD product ion scan from Micromass Ultima Triple Quadrapole Mass Spectrometer 
using electrospray positive ion mode and using analytical procedure stated in section 3.7.0 
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Figure 4.7 CBN full scanning ion chromatogram from Micromass Ultima Triple Quadrapole Mass 
Spectrometer using electrospray positive ion mode with and using analytical procedure stated in 
section 3.7.0 
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Figure 4.8 CBN product ion chromatogram from Micromass Ultima Triple Quadrapole Mass 
Spectrometer using electrospray positive ion mode and using analytical procedure stated in section 
3.7.0 
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Figure 4.9 THC full scanning ion chromatogram from Micromass Ultima Triple Quadrapole Mass 
Spectrometer using electrospray positive ion mode and using analytical procedure stated in section 
3.7.0 
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Figure 4.10 THC product Ion scan from Micromass Ultima Triple Quadrapole Mass Spectrometer 
using electrospray positive ion mode and using analytical procedure stated in section 3.7.0 
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Figure 4.11 THCA full scanning ion chromatogram from Micromass Ultima Triple Quadrapole 
Mass Spectrometer using electrospray positive ion mode and using analytical procedure stated in 
section 3.7.0 
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Figure 4.12 THCA product ion scan from Micromass Ultima Triple Quadrapole Mass Spectrometer 
using electrospray positive ion mode and using analytical procedure stated in section 3.7.0 
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Figure 4.13 CBC full scan ion chromatogram from Micromass Ultima Triple Quadrapole Mass 
Spectrometer using electrospray positive ion mode and using analytical procedure stated in section 
3.7.0 
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Figure 4.14 CBC product ion scan from a Micromass Ultima Triple Quadrapole Mass Spectrometer 
using electrospray positive ion mode and using analytical procedure stated in section 3.7.0 
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4.4.1 Cannabis Sativa Cannabinoids HPLC-UV Spectrophotometer Profile  
 
Figure 4.15 HPLC-UV chromatogram of CBD, CBN, THC and THCA at 200 µg/mL 
 
 
The above chromatogram is a typical chromatographic profile of the 4 major compounds 
found in a cannabis sativa plant.  The retention time shown and peak areas are typical for 
each compound at 200 µg/mL in the HPLC-UV analytical system used here (see section 
3.6.0). 
 
To determine the capabilities of the extraction system, a number of experiments were 
performed.  Each experiment was designed to validate the method in terms of 
reproducibility and efficiency of the extraction system.   
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4.5 Stability of Cannabinoids To Typical Open Flame Combustion   
Standard solutions of CBD, CBN and THC were dried down to solids and combusted.   
The recovery of THC (figure 4.16) was on average over 90% across three different 
concentrations (100, 200 and 400 µg/mL).  Recovery of CBN (figure 4.17) was on 
average over 90% across initial concentrations of 20, 40, and 80 µg/mL.  Recovery of 
CBD (figure 4.18) was on average over 80% across initial concentrations of 20, 40, and 
80 µg/mL.  The reason in the discrepancy for standard concentrations used for THC 
versus CBD and CBN was that in a typical high potency cannabis plant sample, these 
standard concentrations more accurately reflect the amount one would likely find in a 
plant sample (see figure 4.33 and figure 4.34). . 
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Percentage Recovery of THC after open flame combustion
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Figure 4.16 Percentage Recovery for THC across initial concentrations of 100, 200 and 400 µg/mL 
THC before and after combustion 
 
 
 
 
Recovery of CBN after combustion at three different 
concentrations
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Figure 4.17 Percentage Recovery for CBN across initial concentrations of 20, 40 and 80 µg/mL CBN 
before and after combustion 
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Recovery of CBD after combustion at three different 
concentrations
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Figure 4.18 Percentage Recovery for CBD across initial concentrations of 20, 40 and 80 µg/mL CBD 
before and after combustion 
 
 
 
 
4.5.1 Stability of THCA to Open Flame Combustion 
 
It has been hypothesized that THCA is converted to THC upon combustion or 
exposure to heat.  Table 4.13 is the initial amount of THCA analyzed and quantitated 
before combustion.  The same samples were then combusted and analyzed using HPLC-
UV to qualitatively and quantitatively describe the changes.  Table 4.14 is the resulting 
amount of CBN, CBD, THC and CBC quantitated after combustion of the THCA 
standards.  Note that due to the unavailability of a CBC standard, only the peak areas are 
displayed. in the table.  It can clearly be seen that the recovery of THCA is below the 
limit of quantification.  Furthermore, the recovery of THC falls in the range of 49-55% 
across the three different standard concentrations (113, 225 and 450 µg/mL) (figure 
4.19).  Two HPLC-UV chromatograms showing the before and after combustion of the 
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raw cannabinoid plant extract can be found in section 4.11 figure 4.33 and 4.34, 
respectively. 
 
 
 
  
  
Table 4.13 Uncombusted Samples of THCA Standard (µg/mL) 
SAMPLE THCA  
  AMT AREA 
0203-10a 113 THCA liquid 116.3 3390394
0203-10b 113 THCA liquid 111.5 3252342
0203-10c 113 THCA liquid 120.9 3523232
AVERAGE 116.2 3388656
   
0203-11a 225 THCA liquid 246.3 7122012
0203-11b 225 THCA liquid 254.0 7342234
0203-11c 225 THCA liquid 245.7 7103454
AVERAGE 248.7 7189233.3
   
0203-12a 450 THCA liquid 465.8 13420859
0203-12b 450 THCA liquid 449.2 12945455
0203-12c 450 THCA liquid 451.9 13022344
AVERAGE 455.6 13129553
* Three different concentrations of THCA standard before combustion analyzed in 
triplicate on HPLC-UV.  
 
 
 
  78
  
Table 4.14 Combusted Samples of the THCA Standard (µg/mL) 
 CBN  THC  THCA  CBC 
 amt area amt area amt area area 
0203-3b 113 THCA 3M BLQ  29.7 778263 BLQ  1750754.8 
0203-2b 113 THCA 3M BLQ  45.7 1274934 BLQ  1589118.8 
0203-1b 113 THCA 3M BLQ  47.1 1316202 BLQ  1582425.3 
AVERAGE   40.8 1123133   1640766.3 
        
0203-6b 225 THCA 3M 6.3 351440 103.2 3059029 BLQ  1260623.4 
0203-5b 225 THCA 3M 6.6 377001 105.2 3120689 BLQ  1254970.5 
0203-4b 225 THCA 3M 4.8 240604 81.0 2368997 BLQ  1256369.0 
AVERAGE 5.9 323015 96.5 2849571   1257320.9 
        
0203-9b 450 THCA 3M 11.2 725051 173.5 5240320 BLQ  669418.3 
0203-8b 450 THCA 3M 11.3 733056 179.0 5411495 BLQ  593086.4 
0203-7b 450 THCA 3M 11.4 741931 198.2 6006438 BLQ  518554.0 
AVERAGE 11.3 733346 183.6 5552751   593686.2 
        
        
        
SAMPLE CBN  THC  THCA  CBC 
 amt area amt area amt area area 
0203-3a 113 THCA TT 4.9 249234 34.1 915629 BLQ  BLQ 
0203-2a 113 THCA TT 4.5 215986 14.5 306857 BLQ  BLQ 
0203-1a 113 THCA TT BLQ BLQ 17.4 397373 BLQ  BLQ 
AVERAGE 4.7 232610 22.0 539953    
        
0203-6a 225 THCA TT BLQ  22.2 545302.6 BLQ  BLQ 
0203-5a 225 THCA TT BLQ  21.6 525346 BLQ  BLQ 
0203-4a 225 THCA TT BLQ  30.1 790700.5 BLQ  BLQ 
AVERAGE   24.6 620449.7    
        
0203-9a 450 THCA TT BLQ  63.5 1826402 BLQ  BLQ 
0203-8a 450 THCA TT BLQ  48.5 1362525 BLQ  BLQ 
0203-7a 450 THCA TT BLQ  36.9 1002162 BLQ  BLQ 
AVERAGE   49.7 1397030    
        
TOTAL 450   220.5 6554913    
TOTAL 225   121.1 3470021    
TOTAL 113   62.9 1663086    
* Resultant concentrations of CBN, CBC and THC after combustion of THCA standard 
analyzed in triplicate on HPLC-UV.  
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Figure 4.19 Percentage Recovery for THC across initial concentrations of 113, 225 and 450 µg/mL 
THCA before and after combustion. 
 
 
4.6 Capacity of the SPE Method in a Serial Arrangement 
 
Another experiment involved using 2 solid phase extraction cartridges in a serial 
arrangement to see if the first SPE was unable to capture all of the cannabinoids under 
vacuum after being combusted.  Figure 4.20 shows the results of the HPLC-UV analysis 
of the first SPE cartridge.  Again, approximately 50% of the THCA was converted to 
THC which is extracted from the first SPE cartridge.  The second SPE cartridge (figure 
4.21) shows that no cannabinoids were detected giving strength to the argument that the 
first SPE cartridge is capable of detecting and capturing virtually all of the cannabinoids 
in the smoke at this concentration. 
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Figure 4.20 HPLC-UV chromatogram of cannabinoids from first SPE cartridge in a serial 
arrangement. 
 
 
 
Figure 4.21 HPLC-UV chromatogram of  cannabinoids from second SPE cartridge in a serial 
arrangement 
 
 
 
 
 
 
4.7 Capacity of the SPE Method Using Plant Tissue 
 
The capacity of the SPE extraction method was investigated.  This was necessary 
to determine the sample load of the SPE cartridge as employed in the SPE combustion 
system.  
Figure 4.22 shows that the SPE method for THC shows a linear increase in 
capacity as one increases the amount of plant material combusted from 5 mg to 10 mg.  
As the amount is increased further to 15 mg there is an apparent leveling off in the 
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cartridge capacity.  For CBN (figure 4.23), the SPE method shows a linear increase in 
capacity as one increases the amount of plant material combusted from 5 mg to 10 mg.  
As the amount is increased further to 15 mg the cartridge still maintains it linearity in 
response.  For CBD (figure 4.24) and CBC (figure 4.25), there is also a linear increase in 
the response shown between 5 and 10 mg plant samples.  However, the leveling off at 15 
mg is apparent.  Therefore, based on all analytes in the standard plant samples, it appears 
that the SPE cartridge system should be not used with sample sizes greater then 10 mg 
of cannabis plant for the combustion and extraction system as the capacity for extraction 
is reached.  Furthermore, the sensitivity appears to be very good at the 5 mg level and 
hence most of the experiments performed were carried out at this concentration when 
using raw plant samples. 
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Figure 4.22 THC AUC for 5, 10 and 15 mg of combusted cannabis plant material extracted from 3M 
SPE cartridge 
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Figure 4.23 CBN AUC for 5, 10 and 15 mg of combusted cannabis plant material extracted from 3M 
SPE cartridge 
 
 
Average CBD AUC for 5, 10 and 15 mg of combusted cannabis plant 
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Figure 4.24 CBD AUC for 5, 10 and 15 mg of combusted cannabis plant material extracted from 3M 
SPE cartridge 
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Average CBC AUC for 5, 10 and 15 mg of combusted Cannabis Plant 
material extracted from an SPE cartridge
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Figure 4.25 CBC AUC for 5, 10 and 15 mg of combusted cannabis plant material extracted from 3M 
SPE cartridge 
 
 
 
 
4.8 Conversion of THCA to THC and Other Cannabinoids at Different 
Temperatures Held Over a Constant Time Frame 
 
The transition of THCA to THC was investigated using the SPE method and combustion 
system.  This particular experiment involved using a vacuum tight sealed glass vial and 
heating a known amount of plant material and then measuring the concentration of 
THCA/THC at predetermined temperatures.  Each temperature range was held for 30 
minutes.  Table 4.15 and figure 4.26 show the results of this experiment.  The results 
demonstrate that at 50 degrees celcuis, THCA was surprisingly stable and was highly 
recoverable at this temperature (no THC was detected in 3 of the 4 tests and the 
concentration of THCA stayed constant at 236.7 µg/mL).  However, at 100 degrees 
celcius, THCA begins to decompose.  At this temperature there is an almost equal 
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concentration of THCA and THC (87.26 µg/mL THCA compared to 110.45 µg/mL 
THC).  This is interesting because when you go on to the next temperature threshold of 
150 degrees celcius, there is an increase in the concentration of THC but a greater 
concentration of THCA is also destroyed (121.6 µg/mL THC and 11.55 µg/mL THCA).  
At 200 degrees, the only quantifiable compound is CBN.  This is an important 
observation because it gives further weight to the hypothesis that cannabinoids are in 
fact very heat labile compounds and all of which eventually break down into their core 
elements when exposed to excessive heat. 
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Table 4.15 THCA conversion to THC and CBN at Different Temperatures held for 30 minutes. 
THCA Conversion (µg/mL) to THC and CBN at Different 
Temperatures held for 30 minutes 
TEMP 'C SAMPLE CBD CBN THC THCA 
  1 BLQ BLQ BLQ 237.86 
50 2 BLQ 5.94 BLQ 236.47 
  3 BLQ BLQ 13.07 235.13 
  4 BLQ BLQ BLQ 237.50 
  AVERAGE   5.94 13.07 236.74 
            
  5 BLQ 5.42 134.83 88.37 
100 6 BLQ BLQ 104.74 86.62 
  7 BLQ BLQ 100.97 86.41 
  8 BLQ BLQ 101.26 87.63 
  AVERAGE   5.42 110.45 87.26 
           
  1 BLQ 10.12 112.91 BLQ 
150 2 BLQ 10.43 119.01 10.24 
  3 BLQ 10.50 123.26 BLQ 
  4 12.72 10.95 131.21 12.86 
  AVERAGE  10.50 121.60 11.55 
            
  1 BLQ 51.95 BLQ BLQ 
200 2 BLQ 54.88 13.13 BLQ 
  3 BLQ 53.09 12.23 BLQ 
  4 BLQ 56.41 BLQ BLQ 
  AVERAGE   54.08 12.68   
           
  1 BLQ 11.01 BLQ BLQ 
250 2 BLQ 13.81 BLQ BLQ 
  3 BLQ 20.34 BLQ BLQ 
  4 BLQ 15.34 BLQ BLQ 
  AVERAGE   15.13     
** The initial THCA concentration was 240 µg/mL.  The Initial THC concentration was 12.3 µg/mL 
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Figure 4.26 THCA conversion to THC and CBN from 20-250 degrees celcius at different 
temperatures held for 30 minutes. 
 
 
 
 
 
An interesting observation is the 100-degree threshold.  There has been a large amount 
of THC already produced from the THCA.  However, there is still a relatively large 
amount of THCA still quantifiable.  It is somewhere between this temperature and 50 
degrees that is the flash point of the reaction.  Further investigations could prove 
interesting.  Also what is quite fascinating is at the 200 degree mark, CBN is the most 
abundant molecule.  Lastly, at the 250 degree mark virtually all of the cannabinoids are 
at or below the LLQ. 
 
4.9 The Conversion of THCA to Related Cannabinoids as a Function of Time at a 
Single Temperature 
 
The rate of decomposition of THCA to THC at a set temperature was investigated.  
A temperature of 200°C was chosen as it was a temperature that demonstrated both 
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qualitative and quantitative changes in the cannabinoids over a short period of time 
before thermal destruction set in.  Table 4.16 and figure 4.27 show that after 
approximately 1 minute at 200°C, most of the THCA has been converted to THC.  For 
the next 4 minutes, the THC concentrations stay virtually identical despite being heated 
at 200°C.  Simultaneous to the conversion of THCA to THC is the increase in CBN 
concentration that slowly begins to rise after 2 minutes. After 5 minutes, THC 
concentrations start to decrease and continue to decrease rapidly until there is virtually 
none left at 25 minutes.  At the same time, CBN concentrations continue to increase 
right up until the 25 minute mark.  The increase in CBN concentration is most likely 
formed from THC.  Figure 4.28 shows the chemical structural change from THC to 
CBN.  The only change is the loss of the 2 hydrogen atoms on the CBN molecule 
resulting in the formation of an aromatic ring. 
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Table 4.16 Conversion of THCA to THC over 25 minute period at 200 degrees celcius 
 
THCA conversion to THC over 25 minute period at 200 degrees celcius 
Time SAMPLE CBN (µg/mL) THC (µg/mL) THCA (µg/mL % Conversion 
0 Initial BLQ 12.3 260   
      
1 BLQ 149.40 26.80 57.46 
2  153.00 24.00 58.85 
3  152.00 23.00 58.46 
1 
AVERAGE   151.47 24.60 58.26 
      
4 BLQ 152.00 <10  58.46 
5  155.00 <10  59.62 
6  151.00 <10  58.08 
2 
AVERAGE   152.67   58.72 
      
7 7.80 153.00 <10  58.85 
8 6.70 151.00 <10  58.08 
9 8.20 154.00 <10  59.23 
3 
AVERAGE 7.57 152.67   58.72 
      
10 11.70 153.00 <10  58.85 
11 10.70 150.00 <10  57.69 
12 11.40 154.00 <10  59.23 
4 
AVERAGE 11.27 152.33   58.59 
      
13 27.02 157.00 <10 60.38 
14 26.90 159.00 <10  61.15 
15 28.30 158.00 <10  60.77 
5 
AVERAGE 27.41 158.00   60.77 
      
16 39.40 84.40 <10 32.46 
17 40.80 83.30 <10  32.04 
18 38.90 86.30 <10  33.19 
10 
AVERAGE 39.70 84.67   32.56 
      
19 51.30 54.50 <10 20.96 
20 50.80 52.10 <10  20.04 
21 51.90 55.50 <10  21.35 
15 
AVERAGE 51.33 54.03   20.78 
      
22 56.04 38.20 <10 14.69 
23 57.30 36.30 <10  13.96 
24 55.40 39.40 <10  15.15 
20 
AVERAGE 56.25 37.97   14.60 
25       
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25 64.20 <10 <10 N/A 
26 63.60 <10 <10   
27 65.20 <10 <10   
AVERAGE 64.33       
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Figure 4.27 THCA conversion to THC and CBN over a 25 minute period at 200 degrees celcius 
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Figure 4.28 Chemical Structure of THC and CBN.  Note the loss of 2 Hydrogen ions on the upper 
left ring of CBN, which is the only difference between these two compounds. 
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4.10 Other Products from the Thermal Decomposition of THCA 
 
The lack of quantitative conversion of THCA to THC may suggest that other 
compounds not identified during HPLC-UV may account for the apparent loss of 
THCA.  Consequently, samples were analyzed by LC/MS to help identify if other 
cannabinoid type compounds were present after combustion.  All results were obtained 
using both positive and negative electrospray ion modes.  All samples were infused at a 
rate of 1 mL/min.  Figure 4.29 is a full scanning negative ion mass spectrum of the 
methanolic extract of cannabis plant material.  Here a predominant ion at 357 m/z can be 
seen. This ion corresponds to the M-H of THCA.  No other significant cannabinoid 
related ions are present in the mass spectrum.   
 
 
 
Figure 4.29 Full scanning negative ion mass spectrum of the methanolic extract of cannabis plant 
material infused into the mass spectrometer. 
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Figure 4.30 Full scanning positive ion mass spectrum of the methanolic extract of cannabis plant 
material infused into the mass spectrometer. 
 
 
Figure 4.30 is the analogous sample analyzed in positive ion mode where only ions 
related to THC (M+H of THC) 315 molecular weight can be seen.  THCA cannot be 
seen in this ion chromatogram because the acid entity does not protonate easily in an 
organic solvent.  Hence acids are better analyzed under negative ion mode as 
demonstrated above. 
Performing the same experiment now after the plant extract has been combusted 
gives the following results (Figure 4.31): 
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Figure 4.31 Full scanning positive ion mass spectrum of the methanolic extract of combusted 
cannabis plant material infused into the mass spectrometer. 
 
 
Figure 4.31 demonstrates under positive ion mode a large increase in the intensity of the 
THC peak.  Again, there are no extraneous peaks that could account for the 40-50% loss 
of THCA. 
 
 
 
Figure 4.32 Full scanning negative ion mass spectrum of the methanolic extract of combusted 
cannabis plant material infused into the mass spectrometer. 
 
 
Figure 4.32 shows that after combustion under negative ion mode, there is virtually no 
THCA detectable.  Also notice, that although negative ion mode shows much less 
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sensitivity for THC, the quantity of THC is so great after combustion that it can be 
detected now.  
 
 
4.11 Chemo-Botanic Profiling of a Typical Raw Cannabis Plant Extract Before 
and After Combustion 
 
Chemo botanic profiling of a typical raw cannabis plant extract yielded the 
following chromatogram (Figure 4.33): 
 
 
Figure 4.33 HPLC-UV chromatogram of cannabinoids found in typical high potency marihuana 
plant. 
 
Figure 4.33 shows the major cannabinoid present in a typical plant extract is 
THCA with very minor quantities of CBD, CBN, and THC.  The initial concentration of 
THCA in this sample was estimated to be 830 µg/mL.  If this plant sample is combusted 
and the smoke analyzed, the following chromatogram was obtained (figure 4.34): 
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Figure 4.34 HPLC-UV chromatogram of cannabinoids found in a typical high potency marihuana 
plant after combustion. 
 
 
Figure 4.34 shows that there is now a very small quantity of the THCA and a 
large increase in quantity of THC (420 µg/mL).  There was also a small increase in the 
CBN concentration.  The increase in THC concentration only accounts for 
approximately 50% of the initial THCA concentration.  The remainder of the THCA is 
unaccounted for in this conversion process.  Figure 4.35 is the molecular structures of 
THCA and THC.  The only difference is the carboxylic acid group on the number two 
carbon. 
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Figure 4.35 The conversion of THCA TO THC 
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4.12 Other Samples with Differing Concentrations of THCA  
 
For much of the research shown above, a standardized sample marihuana plant 
has been used in order to keep the number of variables in the experiments to a minimum.  
However, below are two other standardized samples of marihuana plant that have known 
differing concentrations of THCA.  A certificate of analysis for sample 1502 states that 
it contains 3% THCA and 0.08% THC.   Table 4.17 and figure 4.36 show the 
concentration of THC found after combustion is equal to 2% THC or 66% of the original 
concentration of THCA.   
  
Table 4.17 Combusted Marihuana plant sample 1502 (µg/mL) Initial concentration of THCA before 
combustion was 154.4 µg/mL 
1502 SAMPLE     
TEST TUBE WALLS MEOH 
RINSE 
    
SAMPLE CBN THC THCA CBC 
1  63.11  735802 
2  75.21  879370 
3  59.96  688951 
4  59.23  689092 
5     
AVERAGE  64.38  748303.8 
STDEV  7.41  90117.4 
     
TEST TUBE WITH 3M 
ATTACHED 3M RINSE 
    
SAMPLE    CBC 
1 2.97 18.92  203197.5 
2  13.81   
3 3.17 23.62  257827 
4 3.67 28.16  284996.3 
5 6.19 103.07  1292538 
AVERAGE 4.00 37.52  509639.7 
STDEV 1.49 37.03  523039.5 
     
TOTALS 4.00 101.90  1257943 
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Certificate of analysis for sample 1505 shows that this sample contained 10% 
THCA and 0.1% THC.  Upon combustion (table 4.18 and figure 4.36) the concentration 
of THC in the sample works out to be 5.7% which is 57% of the original concentration 
of THCA.   This gives further evidence that the conversion of THCA to THC is in the 
order of 50-60%.  Here there is further evidence to support the 50-60% percent 
conversion hypothesis as it has now been shown across different samples of differing 
concentrations of THCA that the ratio of THCA to THC converted remains similar.  
 
Conversion of THCA to THC in two samples (1502 
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Figure 4.36 Conversion of THCA to THC in two diverse cannabis samples #1502 and #1505 that 
contain differing quantities of THCA. 
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Table 4.18 Combusted Marihuana plant sample 1505 (µg/mL).  Uncombusted THCA concentration 
was 506.5 µg/mL 
1505 SAMPLE      
TEST TUBE WALLS METHANOL 
RINSE 
     
SAMPLE CBD CBN THC THCA CBC 
1 12.15 4.55 254.41  865461.2 
2 12.39 4.54 254.50  871730.1 
3 9.77 3.68 209.26  713399 
4 10.30 4.10 215.96  731104.1 
5 11.41 4.14 235.95  788290.5 
AVERAGE 11.20 4.20 234.01  793997 
STDEV 1.14 0.35 21.08  73541.95 
      
      
TEST TUBE WITH 3M ATTACHED 
3M RINSE 
     
SAMPLE      
1  3.24 46.34 20.74  
2  3.31 30.44 16.41  
3  5.03 72.22 27.73 217606 
4  4.22 65.55 20.72 212233.2 
5  3.67 58.96 19.58  
AVERAGE  3.90 54.70 21.04 214919.6 
STDEV  0.74 16.59 4.13 3799.139 
      
      
TOTALS 11.21 8.11 288.72 21.04 1008917 
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4.13 Comparison of Different Smoking Devices - The Analysis of Different Devices 
Used for Inhaling Marihuana 
 
As well as determining the quantitative and qualitative profile of marihuana after 
combustion has occurred, an experiment was also carried out to determine if there are 
any differences in the amount of cannabinoids present in smoke delivered by different 
types of pipes.  As well, a common vaporizer and water bong were also examined to 
determine the cannabinoid profiles arising from these devices and reaching the outlet 
orifice under a specified vacuum.  A random sample of smoking devices was obtained 
from the RCMP and is shown in Figures 4.37-41.  The vaporizer was the only purchased 
device that was obtained from an online internet retailer.  
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Figure 4.37 PIPE #1 donated by RCMP for Marihuana Analysis 
 
Table 4.19 Combustion data for Pipe #1 (µg/mL) 
SAMPLE CBD CBN THC THCA CBC 
1 19.22 11.49 324.64 11.38 679089 
2 22.38 9.61 381.74 9.23 859607 
3 21.32 9.86 347.80 12.92 743461 
4 21.19 11.52 354.42 2.49 751595 
5 21.13 8.86 352.83 14.00 779526 
6 23.41 11.56 432.65 13.57 993654 
7 20.56 11.14 401.35 11.32 828459 
8 22.98 10.36 382.12 14.49 823188 
9 22.97 9.36 378.73 38.85 801149 
10 22.53 11.75 399.10 10.93 827965 
AVERAGE 21.77 10.55 375.54 15.19 808769 
SD 1.31 1.070794 31.44231 9.412854 83662.99 
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Figure 4.38 PIPE #2 donated by RCMP for Marihuana Analysis 
 
Table 4.20 Combustion data for Pipe #2 (µg/mL 
SAMPLE CBD CBN THC THCA CBC 
1 18.01 10.71 316.74  859607.00 
2 25.12 15.42 421.36  659043.97 
3 24.11 13.31 410.08  900141.00 
4 23.54 11.48 404.75 9.24 861888.88 
5 21.91 11.47 368.70  768854.53 
6 23.08 11.84 397.63  853190.00 
7 21.24 11.77 355.00  725839.50 
8 21.53 13.22 370.82 8.56 832271.60 
9 22.30 11.95 374.83  806647.57 
10 20.28 10.44 349.06   742566.06 
AVERAGE 22.11 12.16 376.90 8.90 801005.01 
STDEV 2.04 1.47 32.09 0.48 75242.76 
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Figure 4.39 PIPE #3 donated by RCMP for Marihuana Analysis 
 
Table 4.21 Combustion data for Pipe #3 (µg/mL) 
SAMPLE CBD CBN THC THCA CBC 
1 15.01 7.44 239.79 15.00 695044 
2 17.43 8.48 284.08 14.73 803362 
3 13.21 8.18 221.08 11.15 572194 
4 13.25 6.43 208.17 14.10 572808 
5 16.12 7.26 256.93 12.62 695212 
6 13.40 7.53 216.09 10.39 582313 
7 14.20 7.08 224.86 12.43 631231 
8 15.86 8.87 267.83 17.42 737772 
9 17.06 9.25 281.60 13.99 801427 
10 15.81 8.07 255.13 15.96 726035 
AVERAGE 15.14 7.86 245.55 13.78 681739 
STDEV 1.56 0.86 27.53 2.16 88744 
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Figure 4.40 PIPE #4 donated by RCMP for Marihuana Analysis 
 
Table 4.22 Combustion data for Pipe #4 (µg/mL) 
SAMPLE CBD CBN THC THCA CBC 
1 14.84 7.95 241.85 12.11 648362 
2 10.63 5.24 159.35 7.91 452605 
3 14.24 7.33 225.22 10.42 634415 
4 10.97 6.24 167.78 10.74 503688 
5 9.24 6.66 193.81 11.87 578656 
6 10.68 6.57 217.11 12.17 626717 
7 10.70 5.50 153.12 9.88 448328 
8 13.12 6.31 208.10 10.80 591864 
9 14.98 7.60 241.10 9.10 701760 
10 15.05 6.74 243.95 15.85 714205 
AVERAGE 12.45 6.61 205.14 11.08 590060 
STDEV 2.23 0.85 35.01 2.15 94970 
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Figure 4.41 WATER BONG donated by RCMP for Marihuana Analysis 
  
 
Table 4.23 Combustion data for Water Bong (µg/mL) 
SAMPLE CBD CBN THC THCA CBC 
1 19.24 11.12 180.43 BLQ 871114.5 
2 17.93 8.44 168.92 5.04 793895.2 
3 14.55 11.56 138.41 8.18 668740.8 
4 16.19 8.76 161.32 5.71 750145.7 
5 13.53 8.24 172.77 9.87 772064.9 
6 12.32 6.11 131.06 4.75 652393 
7 13.68 7.62 140.57 2.93 682534.6 
8 17.56 8.65 164.51 4.01 812841.5 
9 16.05 7.68 156.03 4.31 747653 
10 12.73 8.48 164.62 6.13 754746.5 
AVERAGE 15.38 8.66 157.86 5.66 750613 
SD 2.37 1.61 16.18 2.17 68099.19 
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Figure 4.42 VAPORIZER purchased from online retailer for Marihuana Analysis 
 
Table 4.24 Combustion data for Vaporizer taken from walls of vaporizer (µg/mL) 
SAMPLE CBN THC THCA CBC 
1 jar 5.71 103.56  250972.5 
2 jar 3.30 124.24   
3 jar 2.14 105.08  259006 
4 jar 4.07 90.39  249334 
5 jar 5.43 107.72  262297 
6 jar 6.05 139.09  309352.5 
7 jar 7.43 154.76  378535.5 
8 jar 3.63 109.39  298089 
9 jar 4.52 120.63  295605.5 
10 jar 4.31 92.21   213671 
AVERAGE 4.66 114.71   
STDEV 1.53 20.32   
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Table 4.25 Combustion data for Solid Phase Extraction column taken from Vaporizer outlet 
(µg/mL) 
SAMPLE CBN THC 
1 3M SPE 8.69 90.26 
2 3M SPE 9.80 62.45 
3 3M SPE 11.80 62.81 
4 3M SPE 16.40 33.75 
5 3M SPE 26.04 82.57 
6 3M SPE 12.49 78.99 
7 3M SPE 13.04 37.62 
8 3M SPE 10.87 44.77 
9 3M SPE 13.00 38.11 
10 3M SPE 11.35 54.18 
AVERAGE 13.35 58.55 
STDEV 4.92 20.31 
 
 
 
 
 
 
Upon examination of the data above, it can clearly be seen that only a few 
observations can be made.  First of all, the cannabinoid profiles of all the pipes and the 
water bong are very similar.  As well, the amount of cannabinoids captured by the 
extraction system is virtually the same in the pipes and water bong.  However, what is 
interesting is how poorly the vaporizer performs in comparison to the pipes or the water 
bong.  The vaporizer has significantly less THC reaching the extraction orifice.  More 
importantly, most of the THC in the vaporizer is adsorbing onto the glass enclosure.  
The following conclusion could be made that due to the increased dead space in the 
vaporizer, the vacuum level is insufficient to pull the cannabinoids out of the vaporizer 
and into our extraction system.  The results may be improved if a stronger vacuum was 
used.  In addition, it is conceivable that upon prolonged use of the vaporizer the 
adsorptive sites on the glassware will undoubtedly become saturated.  This “seasoning” 
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of the device may in fact improve its performance as measured by the amount of 
deliverable cannabinoids to the extraction systems. 
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5 CONCLUSION 
 
 
Over the last few years there has been a rebirth of research focused around 
marihuana and its metabolites.  Many investigations are under way to study the vast 
pharmacological properties of cannabinoids since it has been definitively shown that 
endogeneous cannabinoids exist in human beings.  Furthermore, cannabinoid receptors 
have also been identified that are beginning to illustrate the complex puzzle that 
cannabinoids can play in vivo.  This research project was undertaken with the premise of 
doing an analysis of the combusted cannabis plant product.  The first hypothesis was to 
determine if the cannabinoid profile of a typical marihuana plant changes upon 
combustion.  With that being said, a series of experiments were completed to construct a 
crude smoking machine that would allow the researcher to capture and analyze the 
smoke of the combusted cannabis plant.  These data could then be compared to data that 
could be generated by analyzing the same plant sample on a HPLC-UV system using a 
known method for qualitatively analyzing and quantitatively analyzing four major 
cannabinoids:  CBD, CBN, THC and THCA.  A comparison was made comparing the 
cannabinoid profiles between the combusted plant sample and the raw plant sample.  It 
was shown that the cannabinoid profile between the raw plant extract and the combusted 
plant extract did in fact change dramatically.  The raw plant extract showed a large 
amount of THCA with very small quantities of CBD, CBN and THC.  Upon 
combustion, the THCA peak completely disappeared and there was a large increase in 
the size of the THC peak and a smaller increase in the amount of the CBN peak.  The 
CBD peak did not change considerably.  This change in the chromatogram profile led to 
another hypothesis that the THCA is converted to THC in large quantities with some of 
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it also being converted to CBN.  It may or may not be directly converted to CBN or it 
may be converted to THC first and then the THC is converted to CBN.   A number of 
experiments were carried out to determine the thermal stability of each of the 
cannabinoids.  This was important, as it would hopefully provide some important 
information as to which cannabinoids were most resistant to thermal breakdown.   
Known quantities of CBD, CBN, THC and THCA standards were all analyzed at 3 
different concentrations and were combusted using the smoking machine.  Each analyte 
was extracted as above and its percentage recovery versus the initial amount of standard 
was noted.  For CBD, the percent recovery for the 20, 40 and 80 μg/mL samples was 
68%, 80% and 96%.  For CBN the percent recovery for the 20, 40 and 80 μg/mL 
samples was 87%, 93% and 94%.   For THC the standard concentrations that were used 
were much higher since it was found in much higher concentrations after combustion.  
The standard concentrations for THC were 100, 200 and 400 μg/mL.  The percent 
recovery after combustion for each concentration was 92%, 93% and 88%, respectively.   
Finally, THCA standard was analyzed and combusted at a concentration of 113, 225 and 
450 μg/mL.  As expected after combustion, virtually all of the THCA was undetectable; 
however a large amount of THC was now appearing.  The amount of THC that appeared 
gave a recovery of 55%, 53% and 49% compared to the original THCA concentrations.    
These were exciting data as they showed that THCA conversion to THC may not be a 
100% conversion reaction.  More experiments were carried out that were designed to 
further test the limits of the smoking machine and corresponding extraction system.  The 
capacity of the solid phase extraction system for products of cannabis combustion 
demonstrated that between 5-10 mg of plant material did not saturate the process when 
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the combustion products were analyzed for CBD, CBN, THC and CBC.  For each 
analyte, the results all followed the same trend:  At 5 mg of sample processed by the 
smoking machine a strong response was noted.  At 10 mg of sample, a corresponding 
doubling of response was noted.  At 15 mg of sample, an apparent saturation of the solid 
phase extraction cartridge began to appear in all of the data as there was no longer a 
complete linear increase in adsorption.  There was an increase but it was less then the 5 
to 10 mg increase.     
 Further validation of the designed smoking machine’s ability to accurately 
capture combusted cannabinoids involved using a second solid phase extraction and 
placing it in a serial arrangement with the first solid phase extraction cartridge.  The 
hypothesis behind this experiment was to show that virtually all of the combusted 
cannabinoids were being detained on the first solid phase extraction cartridge and very 
little if any were making it past the first solid phase extraction cartridge.  Analyzing the 
contents of both cartridges clearly showed that if any cannabinoids were reaching the 
second SPE cartridge, their levels were below the LLQ of our HPLC-UV analytical 
system.    
 A triple quadrapole mass spectrometer was used to verify if other products of 
combustion could be seen that were not showing up on the UV detector.  This 
experiment entailed taking the extracted combusted cannabis plant samples and injecting 
them using direct infusion on to the mass spectrometer.  The mass spectrometer was set 
to electrospray positive and negative ion modes.  Samples of combusted CBD, CBN, 
THC and THCA were analyzed in an attempt to detect if there were any other 
combustion products that were being formed that may have not been detected by the 
HPLC-UV system.  After a thorough analysis, it was determined that no other 
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extemporaneous compounds were being formed from the conversion of THCA to THC 
that could account for the 40-50% loss of analyte.  It has been hypothesized that the 
inexplicable loss of analyte is most likely being broken down into the core elements of 
carbon and hydrogen or as suggested by the investigators into polymeric material that is 
not detectable (either not ionized or chromatographically not detectable).   
 In order to try and follow the conversion of THCA to THC, a high temperature 
programmable oven was used.  This experiment did not use a smoking machine but 
instead a series of pre-defined temperatures.  THCA was heated at 50, 100, 150, 200 and 
250°C for a period of 30 minutes.   It was anticipated that by doing so, the conversion of 
THCA to THC could be examined more carefully and perhaps shed some insight into its 
non quantitative nature.   The results showed that at 50°C, THCA is surprising stable and 
was highly recoverable at this temperature.  However, at 100°C, conversion rapidly 
ensues.  At this temperature there is an almost equal amount of THCA and THC.  This is 
interesting because when you go on to the next temperature threshold of 150°C, there is 
an increase in the amount of THC but a greater amount of THCA is also destroyed.  At 
200°C, the only quantifiable compound is CBN.  This is an important insight because it 
gives further strength to the hypothesis that cannabinoids are in fact very heat labile 
compounds and all of which eventually break down into their core elements when 
exposed to excessive heat. 
 The high temperature oven was used again for more tests.  However, this time, 
temperature was held constant and the dependent variable was time.  A temperature of 
200°C was chosen and time was measured in increments of one to five minutes and then 
from five minutes every five minutes to 25 minutes.   In the first minute, virtually all of 
the THCA is converted to THC.  For the next 5 minutes, the THC levels stay fairly 
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constant and then after 5 minutes they start to decrease with a subsequent increase in 
CBN levels.  This was very interesting as it strongly suggests that CBN is not converted 
directly from THCA but rather is converted from THC.  The CBN levels continued to 
increase right up until the 25 minute mark at which point they began to drop due to 
thermal decomposition.   
 A number of devices used for smoking marihuana were also tested and analyzed.  
A series of pipes borrowed from the RCMP that had been confiscated over the years 
were hooked up to our smoking machine and the resultant cannabinoid profiles were 
evaluated.   As well, a vaporizer purchased from a online marihuana paraphernalia 
company and a water bong were also tested and analyzed.  The results clearly showed 
that the pipes and water bong were all quite similar in cannabinoid profiles.  However, 
the vaporizer consistently delivered less THC to the orifice.  It is a hypothesis that based 
on the vacuum setting that was used, there is too much dead space in the vaporizer and 
hence at the vacuum setting used, there is not enough vacuum to sufficiently pull all the 
cannabinoids out of the orifice.  This was partly confirmed by analyzing the inside of the 
vaporizer where significant amounts of cannabinoids were found bound to the glass 
enclosure.  Furthermore, it is also possible that the glass enclosure requires conditioning 
first by repeated use so the wall of the container becomes saturated with THC.  This may 
also lead to more THC then leaving the orifice after saturation has occurred. 
In summary, experiments were carried out using both HPLC-UV and LC/MS/MS 
data on the combustion of marihuana cannabis plant and its associated cannabinoid 
profiles.  It has been shown that there is a strong likelihood that the decarboxylation of 
THCA to THC during combustion is not a 100% conversion reaction.  Furthermore, the 
data above suggest that the cannabinoids found in cannabis sativa plant are very heat 
  112
labile and hence trying to do quantification using gas chromatography systems may lead 
to inaccurate results.  The current practice of injecting each analyte into the GC and then 
measuring its recovery is flawed as it does not take into account the varying rates and 
amount of thermal decomposition of each compound.  Most interesting in this study was 
the conclusion that under a number of different conditions involving the combustion of 
THCA, the conversion to THC was always between 50-60%.  Furthermore, using the 
same setup for combusting THC, the recovery was always greater then 90%.   
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6 FUTURE DIRECTIONS 
 
One of the goals of this research paper was to validate the contents of combusted 
cannabis plant and to determine if there was a difference between combusted plant 
biochemical constituents versus uncombusted plant biochemical constituents.  The 
research presented here clearly shows that further work in this area of study is 
required to further validate some of the conclusions mentioned above.  Primarily, 
the next line of research should ask the question can the results found here be 
replicated in vivo?  The human breathing model is certainly more complex then a 
simple smoking machine apparatus with respect to peak inspiratory volume, 
velocity and vital capacity.  All of these factors could affect the results seen above.  
One of the primary goals of medical marihuana researchers is to determine if 
marihuana can be consumed via an alternative administration route besides 
inhalation.  Recently, a number of pharmaceutical research companies have come 
up with products that are intended to do just that.  In late 2005, GW Pharmaceuticals 
was approved by Health Canada to sell its sublingual spray that contains a 1:1 ratio 
of CBD and THC (also called cannabis medicinal extract or CME).  As well, there 
is much research ongoing that is trying to reap the positive medical benefits of 
cannabinoids while removing the medically undesirable characteristics of 
marihuana.   
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